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ABSTRACT 
The melanocortin-2 receptor (MC2R) is the most complex due to its trafficking 
and ligand selectivity requirements for proper activation. The MC2R requires the 
melanocortin receptor accessory protein-1 (MRAP1) for proper trafficking and activation 
of the receptor by the melanocortin hormone, ACTH. MRAP1 is a single transmembrane-
spanning domain protein that creates a homodimer with another MRAP1 protein. 
Furthermore, MRAP2 creates a heterodimer with the MC2R. Previous studies have 
shown that the MRAP1 protein contains an activation motif required for activation of 
MC2R and this activation motif located on the extracellular space side of the plasma 
membrane of the cell. The objective of this dissertation was to analyze potential contact 
sites between the extracellular space side activation motif of MRAP1 with the 
extracellular domains of the MC2R—the N-terminal, extracellular loop 1, extracellular 
loop 2, and extracellular loop 3. This analysis utilized a chimeric protein paradigm as 
well as alanine substitution experiments to observe potential contact sites between 
MRAP1 and the MC2R.  By using these approaches, important residues required for 
trafficking or activation were identified in transmembrane 4, extracellular loop 2, and 
transmembrane 5 domains for MC2R. These results propose a revised mechanism for 
MC2R activation. Finally, the revised model suggests evolutionary implications for 
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The melanocortin receptors (MCRs) are a family of hormone-activated receptors that 
influence a number of physiological functions in vertebrates. The melanocortin receptor 
family consists of five different receptors, which were named in the numerical order in 
which they were cloned from the human genome (Cone, 2006). More so, each of these 
receptors is coded on its own gene, and these receptors are expressed in different cells 
and tissues (Cone, 2006) throughout an organism. Melanocortin receptors are G protein-
coupled receptors (GCPRs) that belong to the rhodopsin/β2-adrenergic-like family of 
GPCRs. G protein-coupled receptors are the largest group of cell surface receptors 
(Wettschureck and Offermanns, 2005).  
The MCRs appear to be the smallest GCPRs within their subfamily in terms of amino 
acid length, and have relatively short N- and C- terminal ends (Cooray & Clark, 2011). In 
terms of the location and function of the melanocortin receptors (Cone, 2006), MC1R is 
located on melanocytes, in areas of the brain, and on macrophages. This MCR plays a 
role in pigmentation (melanocytes), body temperature regulation (CNS), and has anti-
inflammatory properties. MC3R is predominantly expressed in the brain, but can be 
found in the placenta, stomach and pancreas; its main function lies in energy metabolism. 




spinal cord where it plays a role in the regulation of food consumption and energy output. 
MC5R is expressed in many different tissues including skin, adrenal and exocrine glands. 
It is thought to play a role in the production of lipids by sebaceous glands of the skin, as 
well as some regulation of the immune system. Finally, MC2R is located in the adrenal 
cortex, and is involved in the initiation of steroidogenesis; the production of the 
glucocorticoid, cortisol. However, this receptor is also expressed in melanocytes, as well 
as, in adipocytes. MC2R is unlike any of the other melanocortin receptors because of its 
unique intracellular trafficking properties and ligand selectivity. 
The MCRs can be activated by different peptide hormones derived from the 
proopiomelanocortin (POMC) gene. This gene is a member of the opioid/orphanin gene 
family (Dores & Baron, 2010). POMC is expressed in the pituitary gland and is 
responsible for the production of POMC proproteins in the corticotropic and 
melanotropic cells of the pituitary. Selective post-translational cleavage in the anterior 
and intermediate pituitary produces the melanocortin hormones adrenocortincotropin 
(ACTH), γ-MSH, α-MSH, and β-MSH (Dores & Baron, 2010). Of the five melanocortin 
receptors (i.e., MC1R, MC2R, MC3R, MC4R, MC5R) that have been characterized in 
vertebrate genomes, activation of these receptors by melanocortin peptides (i.e., ACTH 
or the MSH-sized ligands) is fairly uniform with one exception: MC2R, as demonstrated 
by the human ortholog of this receptor (Cone, 2006; Sebag & Hinkle,2007).  First, one of 
the unique characteristics of the human melanocortin-2 receptor (hMC2R) is that this 
receptor has a strict requirement for interaction with the melanocortin-2 receptor 




and activation of the receptor by ACTH (Metherell et. al, 2005). However, the other 
melanocortin receptors (MCRs) do not have an obligatory requirement for MRAP1 to 
facilitate trafficking or activation (Sebag and Hinkle, 2009).  
Of these five melanocortin receptors, MC2R orthologs require interaction with 
MRAP1, to facilitate trafficking to and activated at the plasma membrane of a respective 
target cell (Hinkle and Sebag, 2009).  MRAP1 is a single-chain polypeptide with a single 
transmembrane spanning domain. MRAP monomers form an antiparallel homodimer 
(Sebag & Hinkle, 2007), hence the homodimer has reverse topology (Figure 1). In 
humans, there are two isoforms of MRAP1, α- and β-, which are the result of alternative 
splicing of exons of the MRAP1 primary transcript (Metherell et al., 2005). Interestingly, 
in other tetrapods and teleosts the MRAP1 mRNA does not appear to undergo alternative 
splicing. Furthermore, mutations in MRAP1 cause familial glucocorticoid deficiency type 
II (FGD II) (Webb & Clark, 2010). 
 In terms of the primary sequence of MRAP1 orthologs, there are three distinct 
domains that are required for successful trafficking and activation of MC2R. For 
example, in mouse MRAP1 (Figure 1), residues 38-61 (transmembrane domain) are 







Figure 1: Schematic of mammalian MRAP1. Adapted from Webb and Clark (2010). 
MRAP1 forms a homodimer with reverse topology. In the N-terminal domain residues 
18-21 (dark green) are the activation motif. Residues 31-37 are responsible for reverse 
topology (blue). Residues 38-61 in the TM region are responsible for trafficking (red). 
of MC2R to the plasma membrane. In the N-terminal domain, residues 31-37 are required 
for the reverse topology of MRAP1 (Shown in Figure 1). Finally, the activation motif, 
LDYL (18-21), is located in the N-terminal of MRAP1 (Shown in Figure 1), and alanine 
substitution at these amino acid positions completely blocks activation of MC2R (Sebag 
and Hinkle, 2009). This level of organization is found in the other tetrapod and teleost 
MRAP1 orthologs that have been characterized (Dores et al., 2016). 
It should be mentioned that MRAP2, a paralog of MRAP1, is found in adrenal 
cortex cells (Chan et. al., 2009). The human MRAP2 gene, C6orf117, is found on a 
different chromosome than the MRAP1 gene (Chan et al. 2009). Like MRAP1, MRAP2 
has a single membrane spanning domain. Since the dimerization domain (Figure 2) is 
conserved between MRAP1 and MRAP2, MRAP2 is able to create an antiparallel 
homodimer (Webb and Clark, 2010). Sebag and Hinkle (2009) showed that the mouse 
MRAP2 (mMRAP2) is able to traffic hMC2R to the plasma membrane, but mMRAP2 




seen in Figure 2, sequence alignments of mMRAP1 and mMRAP2 indicate that the N-
terminal and transmembrane domains are conserved, but the MRAP2 paralog lacks the 
activation motif (Sebag & Hinkle, 2007).  
 
Figure 2: Alignment of mMRAP1 and mMRAP2 sequences. Mouse (m) MRAP1 
(Accession #: NM_029844) mMRAP2 (Accession #: NP_001094952.2) were aligned as 
described in Dores et al. (1996).  
Studies by Hinkle (Sebag and Hinkle, 2007, Sebag and Hinkle, 2009) and Clark 
(Cooray et al., 2008; Webb and Clark, 2010, Cooray et. al., 2011) have shown that MC2R 
and MRAP1 form a heterodimer at the ER. The heterodimer traffics to the plasma 
membrane, and at the plasma membrane an ACTH binding event activates the 
MC2R/MRAP heterodimer. Sebag and Hinkle (2009) found that the TM region of 
MRAP1 is responsible for trafficking by making contact with a TM region of MC2R. 
However, it is unknown which TM on MC2R is making contact with the TM of MRAP1 
to facilitate trafficking to the plasma membrane in Figure 3. In addition, since MRAP1 is 
a homodimer with reverse topology, and there is an activation motif on each MRAP 




loop on MC2R, an intracellular loop on MC2R, or extracellular and intracellular loop of 
MC2R to facilitate activation of the receptor? In Figure 3, the MRAP1 homodimer is 
shown alone as well as creating a heterodimer with the MC2R. Note that the MRAP1 
activation motifs are shown in green with one motif oriented towards the extracellular 
space while the other motif is positioned on the intracellular space. 
 
Figure 3: MC2R and MRAP1 create a heterodimer at the plasma membrane of a 
cell. The MRAP1 activation motifs are shown in green. One monomer’s activation motif 
is oriented on the extracellular space side while the other monomer’s activation motif is 
positioned on the intracellular side of the cell. 
Recently, Malik et al. (2015) using a chimeric protein paradigm strategy, found 
that the activation motif on the N-terminal of mMRAP1 facing the extracellular space 
side of the plasma membrane is responsible for the activation of MC2R. This conclusion 
was based on the following set of experiments. In this study (Figure 4), the “wild-type” 
chimeric receptor consisted of two MRAP1 proteins that were connected to each other by 
a linker region while another linker region connected the hMC2R to the second MRAP1 
protein. When this “wild-type” chimeric protein was expressed alone in HEK-293 cells 
and stimulated with human ACTH(1-24), activation of the chimeric receptor was 






between the MRAP monomers and the MC2R are shown in blue, and the activation 
motifs of MRAP are shown in green. 
 
Figure 4: The “wild type” chimeric protein. The activation motifs of the MRAP1 
monomer 1 and monomer 2 are shown in green while the linker regions of the chimeric 
protein are shown in blue. When the “wild type” chimeric protein was expressed alone in 
HEK-293 cells and stimulated with human ACTH(1-24), activation was observed. 
When the “wild type” chimeric MRAP1/MC2R cDNA was expressed in HEK293 cells 
the corresponding chimeric receptor trafficked to the plasma membrane, and could be 
activated by ACTH. 
However, this initial experiment did not resolve whether the extracellular or 
intracellular activation motif was making contact with hMC2R. Therefore, two different 
chimeric mutant receptors were made to address this question (Figure 5). In the first 
mutant chimeric (Mutant 1), the activation motif positioned on the intracellular space side 
was replaced with alanines (Figure 4). For the second mutant chimeric (Mutant 2), the 
activation motif positioned on the extracellular space side was replaced with alanines 
(Figure 5). Figure 5 illustrates the two chimeric receptors where the alanine substitutions 
at the two activation motifs of the MRAP monomers are shown in red. Each chimeric 




ACTH(1-24). Interestingly, the mutant 1 chimeric receptor could be activated, however, 
the mutant 2 chimeric receptor could not be activated in this experiment.  
 
Figure 5: The mutant 1 and 2 chimeric proteins. The alanine substitutions of the 
MRAP1 monomer activation motifs are show in red. The first mutant substituted alanines 
at the activation motif oriented on the intracellular space side of the cell while the second 
mutant substituted alanines positioned on the extracellular space side of the cell. Each of 
these mutants were expressed in HEK-293 cells and stimulated with human ACTH(1-24). 
The mutant 1 chimeric protein resulted in activation while the mutant 2 chimeric protein 
resulted in no activation. 
To confirm that the activation motif on the mutant 1 chimeric receptor was 
responsible for the activation observed in the previous experiment, a new mutant 
chimeric receptor was made. The final mutant chimeric receptor had the following 
features: the MRAP1 activation motif oriented on the intracellular space was replaced 
with alanines; and an alanine was substituted for the glutamic acid (E) at position 80 in 
MC2R. The design for the new chimeric mutant receptor was based on an earlier site-
directed mutagenesis study. Chen et al. (2007) found that substitution of an alanine at 
position E80 completely blocked activation of hMC2R. Figure 6 illustrates the most 




activation motif of the MRAP1 monomer facing the extracellular side whereas the red 
shows the alanine substitution of the MRAP1 monomer activation motif on the 
intracellular side. Furthermore, an arrow points to the critical amino acid position, E80, in 
hMC2R. When this mutant chimeric receptor was expressed alone in HEK-293 cells 
there was no activation following stimulation of ACTH(1-24). Hence, the mutant 
chimeric receptor is completely inactivated. However, cell surface ELISA analysis 
showed that this new mutant chimeric receptor was on the plasma membrane. In a second 
experiment, wild type MC2R was co-expressed with the new mutant chimeric receptor as 
shown in Figure 6 and stimulated with human ACTH(1-24). Note that when wild type 
MC2R is expressed alone in HEK-293 cells the receptor does not traffic to the plasma 
membrane and there is no activation. However, when wild type MC2R is co-expressed 
with the new mutant chimeric MC2R/MRAP as shown in Figure 6 activation was 
observed following stimulation with human ACTH(1-24).  This experiment provides 
additional evidence that the activation motif of MRAP1 is interacting with an 











Figure 6: Final chimeric experiment. The final chimeric substituted alanines at the 
activation motif of the MRAP1 monomer positioned on the intracellular side of the cell. 
Furthermore, an alanine was substituted at position E80 on the MC2R of the chimeric 
protein. Previous studies have shown that substitution at this position completely 
inactivates MC2R. Wild-type MC2R was co-expressed with the final chimeric protein in 
HEK-293 cells. The cells were stimulated with human ACTH(1-24), and activation was 
observed.  
While the preceding experiments by Malik et al. (2016) clearly demonstrate the 
importance of the activation motif in MRAP1 for orienting the MC2R in a confirmation 
that allows for ACTH binding, it is important to identify the motifs in ACTH that are 
making contact with the MC2R. Shown in the figure below, ACTH is a polypeptide 
hormone that is 39 amino acids in length. Schwyzer (1977) found that only the first 24 
amino acids of ACTH, [ACTH(1-24)], are needed to stimulate glucocorticoid production. 
Note that the sequence for α-MSH is found in the first 13 amino acids of ACTH(1-24). 
While both melanocortin peptides contain the critical amino acid sequence HFRW which 
is required for activating all melanocortin receptors, α-MSH cannot activate the hMC2R. 
Interestingly, α-MSH is not able to activate either tetrapod or teleost MC2R orthologs 
(Mountjoy et al., 1994; Chen et al., 2007; Agulleiro et al., 2010). Schwyzer (1977) 
addressed this paradox by observing that the KKRR motif (Figure 7) present in ACTH(1-




there are two amino acid motifs involved in the activation process: the HFRW motif and 
KKRR motif (Schwyzer, 1977). 
 
Figure 7: Human ACTH, ACTH Analogs, and α-MSH Amino Acid Sequences. The 
HFRW motif is shown in green while the KKRR motif is shown in red. ACTH and α-
MSH share the important HFRW motif, but not the KKRR motif. Schwyzer (1977) 
showed that the KRR motif is required for activation of the MC2R.  
The current model for the activation of hMC2R is presented in Figure 8.  When 
hMC2R is co-expressed with a mammalian MRAP1, the heterodimer will form in the ER 
and will move to the plasma membrane (Figure 8A). However at this stage, the HFRW 
binding site (shown in yellow) is closed.  When ACTH(1-24) makes contact with 
hMC2R, the current model proposes that the KKRR motif on ACTH(1-24) binds to a site 
within the TM4/EC2/TM5 domain (Figure 8A). This binding event triggers a 
conformational changes in the receptor that results in the opening of the HFRW binding 
site (Figure 8B) so that the HFRW motif on ACTH(1-24) can dock with this binding site. 
This event results in an additional conformational change in the receptor that activated 
the G protein to initiation the intracellular communication event (Dores, 2017). 




Figure 8: Proposed model of hMC2R activation by ACTH binding. A. The human 
MC2R takes on a barrel-like shape at the plasma membrane of a cell. When stimulated 
with human ACTH, the KKRR motif (shown in red) of ACTH docks at the proposed 
TM4/EC2/TM5 domain of MC2R (Dores et al., 2016; Liang et al., 2013; Davis et al., 
2013; Dores, 2018). This binding even causes a conformational change in the receptor. B. 
This conformational change in the receptor causes the HFRW binding pocket to be 
exposed for the HFRW motif of ACTH to bind to the receptor. The HFRW binding site 
of the human MC2R is shown in yellow; the HFRW binding site of MC2R is located in 
TM2, TM3, TM6, and TM7 (Pogosheva et al., 2005,; Chen et al., 2007; Dores, 2009). 
             Support for this model comes from multiple studies. All melanocortin receptors 
have an HFRW binding site that involves amino acid positions located on TM2, TM3, 
TM6, and TM7; these residues are located close to the extracellular space (Pogosheva et 
al., 2005,; Chen et al., 2007; Dores, 2009). With respect to the KKRR binding site, work 
in our lab using a single alanine substitution paradigm for human, frog, and rainbow trout 
MC2R orthologs indicated that critical residues in Extracellular Loop 2 (EC2) and TM5 
of MC2R appear to provide the binding site for the KKRR motif of ACTH (Dores et al., 




Based on the preceding observations, there are four working assumptions for this 
thesis. First, there are three distinct sites in MC2R: an HFRW binding site, a KKRR 
binding site, and a MRAP1 activation motif binding site. Second, the MRAP1 activation 
motif (LYDL/I) is located on the N-terminal of the MRAP1 monomer that is positioned 
on the extracellular space side of the plasma membrane (Figure 1). Therefore, MRAP1 
must make contact with an extracellular domain of MC2R. Third, the KKRR binding 
site is predicted to be in the TM4/EC2/TM5 domain (Dores et al., 2016). Hence, two 
hypotheses are proposed to explain the interaction between MRAP1 and MC2R. For 
Hypothesis 1, the potential targets for MRAP1 interaction with MC2R could be: the N-
terminal domain, EC1, or EC3. To test this hypothesis chimeric protein experiments will 
be conducted to determine whether the N-terminal domain, the EC1 domain, or the EC3 
domain contain the contact site for interaction with the activation motif of MRAP1. 
Based on the results of these experiments, multiple and single alanine substitution 
paradigms will be used to determine which amino acid positions within the predicted 
receptor contact site interact with the activation domain of MRAP1.  Finally, if none of 
these three domains can be shown to interact with MRAP1, then the alternative 
hypothesis (Hypothesis 2) is that the MRAP1/MC2R contact point is within the 
TM4/EC2/TM5 domain, and as a result MRAP1 and the TM4/EC2/TM5 domain may 
interact to create the KKRR binding site to facilitate activation of the MC2R. 





CHAPTER 1:  Designing Chimeric MC2R receptors 
In order to identify which extracellular domain on the human melanocortin-2 
receptor (hMC2R) is making contact with melanocortin receptor accessory protein 1 
(MRAP1), a chimeric receptor paradigm was used. In order to use this paradigm it was 
essential to identify a melanocortin receptor that does not require MRAP1 for activation. 
The rationale for using the chimeric protein paradigm is that the exchange of an 
extracellular domain from the non-MRAP-dependent melanocortin receptor with an 
extracellular domain from the MRAP1 dependent receptor (i.e. hMC2R) may make it 
possible to identify the MC2R/MRAP1 extracellular loop contact site. To create these 
chimeric receptors, two criteria needed to be met. First, the receptor’s extracellular 
domains needed to be similar in length to the extracellular domains of hMC2R. Second, 
within the receptor and hMC2R extracellular domains, primary sequence identity needed 
to be low. 
First, a screening process was implemented to compare the length of the hMC2R 
extracellular domains to the extracellular domains of other melanocortin receptors. An 
alignment of the hMC2R, Xenopus tropicalis MC1R (xtMC1R), xtMC3R, and 
Callorhinchus milii or elephant shark esMC3R (esMC3R) are shown in Figure 9. These 




receptors required co-expression with MRAP1 for activation when expressed in CHO 
cells (Dores unpublished data). This figure shows that the extracellular domain 1 (EC1), 
extracellular domain 2 (EC2), and extracellular domain 3 (EC3) of xtMC1R, xtMC3R, 
and esMC3R are all similar in length when compared to the hMC2R. However, when 
comparing the N-terminal (NT) of these receptors to hMC2R there is a difference in the 
length (Figure 9). The NT of hMC2R is 26 amino acids in length. The xtMC1R is shown 
to have 30 amino acids in its NT domain. The NT of xtMC3R is 47 amino acids in length, 
and esMC3R is shown to have 37 amino acids in its NT domain. In an earlier study that 
used hMC2R and hMC4R chimeric receptors, it was shown that swapping out the N-
terminal and TM1 of hMC2R with the N-terminal and TM1 of hMC4R resulted in 
interference with activation of the chimeric receptor (Hinkle et al., 2011). In this 
experiment, it appeared that  the larger size of the N-terminal of this chimeric receptor 
was thought disrupt folding of the chimeric receptor and non-specifically block 
activation. To negate this issue, the xtMC1R was used to make this study’s chimeric 
receptors because of its similar length in the N-terminal to the N-terminal of the hMC2R, 









               N-terminal                         [--------TM1-------   
h  MKH---------------------IINSYENINNTARNNSDCPRVVLPEEIFFTISIVGVLEN 42            
x1 MLH----------------STVNSTNATINVGTELKPTNTSDTVMDVPEELFLFLCVFSLLEN 47           
x3 MSAKAFAMNTTNVFSVQAVLANATLDPNETLFLSNLSRIGFCEQVLIKTEVFLTLGIISLLEN 63             
e3 M----------NSTHFLFDLQLNGSGDLNKSSILNRSNPGFCEQVPIKSEVFLTLGIISLLEN 53 
   ------]   IC1     [---------TM2---------]        EC1        [-- 
h  LIVLLAVFKNKNLQAPMYFFICSLAISDMLGSLYKILENILIILRNMGYLKPRGSFETTADDI 105           
x1 ILVVIAIFRNHNLHSPMYYFICCLAASDMLVSSSNLGETLIIFMLKQGIIKSEPLLVKKMDYI 110           
x3 ILVILAILKNKNLHSPMYFFLCSLAVADMLVSVSNALETIVI-AIQNKYLVIGDYLLQHLDDV 126          
e3 ILVILAILKNKNLHSPMYFFLCSLAVADMLVSVSNALETIVMALLNNGYLVANDQFIQIMDNV 116                                                                      
   --------TM3---------]        IC2       [---------TM4---------] 
h  IDSLFVLSLLGSIFSLSVIAADRYITIFHALRYHSIVTMRRTVVVLTVIWTFCTGTGITMVIF 168                
x1 FDTMICCSLVTSLSFLGAIAIDRYITIFYALRYHSIMTLRRVVIAIGVIWSVSLVCAAIFIVY 173            
x3 FDSMICISLVASICNLLVIAIDRYITIFYALRYHSIMTVKKAIALIVVIWTSCIICGIVFIVF 189          
e3 IDSLICISLVASICNLLVIAIDRYITIFYALRYHSIMTVKRALLLIIVIWIACIFCGIIFIIY 179   
     EC2   [--------TM5--------]             IC3            [----- 
h  SHHVPTVITFTSLFPLMLVFILCLYVHMFLLARSHTRKISTLPRANN----------MKGAIT 221           
x1 HESRAVILCLIVFFLFMLALMVALYIHMFALARQHARSISALQKGKSRRITPHQARAMKGAIT 236          
x3 SESKTVIVCLITMFFTMLVLMATMYVHMFLFARLHVKRIAALPVDGVVQQRTC----MKGAIT 248          
e3 SNSKTVIICLITMFFTMLVLMTTLYVHMFMLARLHIKKIAALPVDGIVRPRTC----MKGAIT 238 
   ---TM6-----------------]    EC3    [----------TM7---------] 
h  LTILLGVFIFCWAPFVLHVLLMTFCPSNPYCACYMSLFQVNGMLIMCNAVIDPFIYAFRSPEL 284           
x1 LTLLLGVFFLCWGPLFLHLTLFVSCPGHHICNSYFYYFNIYLLLVICNSVIDPLIYAFRSQEL 299          
x3 ITILLGVFVVCWAPFFLHLILIISCPSNSYCVCYTSYFNTYLILIMCNSIIDPLIYAFRSLEM 311          
e3 ITILLGIFIICWAPFFLHLILIISCPKNAYCICYTSHFNTYLILIMCNSVIDPMIYAFRSQEM 301                                                
      C-terminal 
h  RDAFKKMIFCSRYW                                                  298                                                           
x1 RKTLKEIVWCSW                                                    311          
x3 RKTFKEIICCYGMNFGKCG                                             330          
e3 RKTFKEIACCYGMNLNSRFSVHRINAAETERTSESSCHCDFGKTSVFNQVALS           354           
Figure 9: Sequence Alignment of hMC2R, xtMC1R, xtMC3R, and esMC3R This 
figure shows an alignment of the hMC2R, xtMC1R, xtMC3R, and the esMC3R. This 
alignment was used to compare the extracellular domains of xtMC1R, xtMC3R, and 
esMC3R to the extracellular domains of hMC2R. xtMC1R, xtMC3R, and esMC2R were 
selected because none of these receptors required co-expression with an MRAP1 for 
activation when expressed in CHO cells (Dores unpublished data). The extracellular 
domains of interest included the N-terminal, extracellular domain 1, extracellular domain 








Figure 10A: xtMC1R co-expressed with or without mMRAP1 stimulated with 
hACTH(1-24) or NDP-MSH A) This figure shows the xtMC1R expressed alone (the 
curves shown in red or green) or co-expressed with mMRAP1 (the curves shown in blue 
or black). The reactions were either stimulate with hACTH(1-24) or NDP-MSH at 
concentrations of 10-6 to 10-12 M. B) Cell surface ELISA analysis of xtMC1R co-
expressed with mMRAP1. xtMC1R +/- co-expression with mMRAP1 was analyzed 
using a cell surface ELISA assay and statistically evaluated using Student’s t-test. n = 3.   
        Although our lab has shown that the xtMC1R does not require MRAP1 for 
activation, there is still the question of whether MRAP1 interfering with the activation of 
this receptor. Figure 10A illustrates an activation assay of xtMC1R expressed alone or 




hACTH(1-24) or NDP-MSH at concentrations ranging from 10-6 to 10-12 M. These results 
show no significant difference in activation of the xtMC1R in the absence of mMRAP1 
(shown in red) or presence of mMRAP1 (shown in blue) when xtMC1R was stimulated 
with hACTH(1-24). The EC50 value for xtMC1R expressed alone was 6.8 x 10
-10 M +/- 
1.5 x 10-10. The EC50 value when the receptor was co- expressed with mMRAP1 and 
stimulated with hACTH(1-24) is 7.8 x 10-10 M +/- 9.3 x 10-11.  A F-test indicated a p-
value of  0.84, which is not statistically significant. Similarly, there was little difference 
in activation of xtMC1R in the absence of mMRAP1 (shown in green) or presence of 
mMRAP1 (shown in black) when stimulated with NDP-MSH. The EC50 value for 
xtMC1R expressed alone was 4.5 x 10-11 M +/- 1.4 x 10-11, and when the receptor was co-
expressed with mMRAP1 the EC50 value was 8.6 x 10
-11 M +/- 4.1 x 10-11. A F-test 
calculated a p-value of  0.95 showing no statistical difference. Overall, these results 
illustrate two important conclusions. First, they show that xtMC1R expression and 
activation is not dependent on co-expression of mMRAP1. Second, they show that 
xtMC1R expression and activation is not negatively affected by co-expression of 
mMRAP1. In addition, co-expression with mMRAP1 does not have any effect, positive 
or negative, on the trafficking of xtMC1R (Figure 10B; p = 0.10; t-Test). 
Figure 11 illustrates the amino acid sequence alignment of hMC2R and xtMC1R 
as well as the sequence identity between hMC2R and xtMC1R in their respective 
transmembrane domains and extracellular loops. First, Figure 11A shows the alignment 




interest are denoted in red; this includes the N-terminal (NT), extracellular loop 1 (EC1), 
extracellular loop 2 (EC2), and extracellular loop 3 (EC3) of the receptors.  
A. Alignment of Human MC2R and Xenopus tropicalis MC1 
                     N-terminal                  [---------TM1----------] 
hMC2 MKH-------------------IINSYENINNTARNNSDCPRVVLPEEIFFTISIVGVLENLIVLLAVF 
xMC1 MLH--------------STVNSTNATINVGTELKPTNTSDTVMDVPEELFLFLCVFSLLENILVVIAIF 
         IC1   [---------TM2---------]        EC1        [---------TM3---- 
hMC2 KNKNLQAPMYFFICSLAISDMLGSLYKILENILIILRNMGYLKPRGSFETTADDIIDSLFVLSLLGSIF 
xMC1 RNHNLHSPMYYFICCLAASDMLVSSSNLGETLIIFMLKQGIIKSEPLLVKKMDYIFDTMICCSLVTSLS 
     ------]       IC2        [---------TM4---------]   EC2   [------TM5-- 
hMC2 SLSVIAADRYITIFHALRYHSIVTMRRTVVVLTVIWTFCTGTGITMVIFSHHVPTVITFTSLFPLMLVF 
xMC1 FLGAIAIDRYITIFYALRYHSIMTLRRVVIAIGVIWSVSLVCAAIFIVYHESRAVILCLIVFFLFMLAL 
     ----------]          IC3              [------------TM6------------] 
hMC2 ILCLYVHMFLLARSHTRKISTLPRANN----------MKGAITLTILLGVFIFCWAPFVLHVLLMTFCP 
xMC1 MVALYIHMFALARQHARSISALQKGKSRRITPHQARAMKGAITLTLLLGVFFLCWGPLFLHLTLFVSCP 
         EC3   [---------TM7---------]    C-terminal 
hMC2 SNPYCACYMSLFQVNGMLIMCNAVIDPFIYAFRSPELRDAFKKMIFCSRYW 
xMC1 GHHICNSYFYYFNIYLLLVICNSVIDPLIYAFRSQELRKTLKEIVWCSW 
                                                   
B. Sequence Identity for hMC2R and xMC1R by domain 
                             %Identity 
N-terminal 10%     EC1      16%     EC2   0%      EC3        33%     
TM1        38%   TM3      33%   TM5  38%      TM7     52% 
IC1        64%     IC2      67%   IC3  28%      C-terminal 39% 
TM2     39%     TM4      26%    TM6    63% 
 
Figure 11: Alignment of hMC2R & xtMC1R A. The sequence alignment of hMC2R 
and xtMC1R. The extracellular domains of interested are shown in red. Also, B. 
illustrates the sequence identity between the hMC2R and xtMC1R. Again, the 
extracellular domains of interest are shown in red. 
Second, Figure 11B shows primary sequence identity between all domains of 
hMC2R and xtMC1R. The domains denoted in red are the extracellular loops of interest. 
The N-terminal domains of hMC2R and xtMC1R have 10% primary sequence identity. 
The EC1 domains of hMC2R and xtMC1R have 16% primary sequence identity. The 
EC3 domains of hMC2R and xtMC1R have 33% primary sequence identity. Most 
interestingly, the EC2 domain of xtMC1R has no primary sequence identity when 





Based on the results presented in Figure 10, and the alignment of xtMC1R and 
hMC2R presented in Figure 11, xtMC1R appeared to be a very good candidate for the 
chimeric receptor experiment.  xtMC1R has and N-terminal domain that is comparable in 
length to the N-terminal domain of hMC2R, and the relatively low primary sequence 
identity between xtMC1R and hMC2R extracellular domains was another favorable 





CHAPTER 2: Evaluation of the N-terminal hMC2R Chimeric Receptor 
       For the first chimeric receptor experiment, the N-terminal domain of the hMC2R was 
replaced with the N-terminal of xtMC1R (Figure 12A). In this experiment the wild-type 
hMC2R (positive control) had an EC50 value of 8.1 x 10
-12 M +/- 3.3 x 10-12 , and the 
xtMC1R N-terminal/hMC2R chimeric receptor had an EC50 value of 1.1 x 10
-9 M +/- 4.7 
x 10-10 ; a nearly 1000 fold decrease in sensitivity for stimulation by hACTH(1-24) that 








A. B.  
Figure 12: Analysis of the xtMC1R/hMC2R N-terminal Chimeric receptors.  A) The 
N-terminal domain of hMC2R was replaced with the N-terminal of xtMC1R (Figure 11) 
to make the xtMC1R/hMC2R N-terminal chimeric receptor. Wild-type hMC2R (red dose 
response curve) and the chimeric N-terminal receptor (blue dose response curve) were 
separately co-expressed with mMRAP1 in CHO cells as described in Methods. The 
chimeric N-terminal receptor was also expressed alone (green dose response curve. 
(n=3). B) A second xtMC1R/hMC2R chimeric receptor was made in which D26 
(xtMC1R; Figure 11) was replaced with C26. Wild-type hMC2R (red dose response 
curve) and the chimeric N-terminal receptor (C26) (blue dose response curve) were 
separately co-expressed with mMRAP1 in CHO cells as described in Methods. The 
chimeric N-terminal receptor C26 was also expressed alone (green dose response curve. 
(n=3). 
However, when the xtMC1R N-terminal/hMC2R chimeric receptor was expressed in the 
absence of mMRAP1 no activation was evident (green curves shown in Figure 12A). 
Hence, exchanging the N-terminal of xtMC1R with the N-terminal of hMC2R did not 
make the chimeric receptor MRAP independent.  
 Although Figure 12A seemed to indicate a role for the N-terminal domain of 
hMC2R in the activation of the receptor, an earlier study reported that there is an 
important cysteine residue located at position 21 in the N-terminal of hMC2R (Figure 11; 




contain this residue in its N-terminal domain (Figure 11). Therefore, a new chimeric N-
terminal xtMC1R/hMC2R was made with a cysteine inserted at residue D26 in the N-
terminal of xtMC1R. Shown in 12B, this experiment’s results show the wild-type 
hMC2R (positive control) had an EC50 value of 8.1 x 10
-12 M +/- 3.3 x 10-12, and the 
xtMC1RN-terminal/hMC2R chimeric receptor with the  C26 substitution had an EC50 
value of 8.5 x 10-12 M +/- 5.1 x 10-12. The replacement of this important cysteine 
recovered activation of the xtMC1R/hMC2R N-terminal chimeric (t-test; p = 0.5). 
Furthermore, when the xtMC1R/hMC2R N-terminal chimeric with C26 was expressed 
alone, no activation occurred.  
Conclusions 
Based on the results of observed in Figure 12B, exchanging the N-terminal of hMC2R 
with the N-terminal of xtMC1R and replacing position D26 with a cysteine residue did not 
interfere with the activation of the chimeric receptor, and did not make the chimeric 
receptor MRAP1 independent. All MC2R orthologs have a cysteine residue in their N-
terminal domain, hence the N-terminal domain is important for maintaining the correct 
conformation of the MC2R, but the results presented in this chapter indicate that the N-
terminal domain of hMC2R is not a likely site for making contact with the activation 
motif on MRAP1.  
        Interest in the N-terminal domain comes from the Fridmanis et al. (2010) study that  
proposed that the N-terminal of hMC2R contained a signal that blocked trafficking 
(referred to as a stop transfer sequence). The stop-transfer hypothesis was proposed to 




receptor was retained in the endoplasmic reticulum. The authors rationalized that when 
hMC2R was co-expressed with MRAP1, the “stop-transfer” sequence was blocked in 
some manner. To test this hypothesis, the N-terminal of human MC4R (43 amino acids in 
length) was exchanged with the N-terminal domain of human MC2R (25 amino acids in 
length) and the chimeric hMC2R N-terminal /hMC4R receptor was expressed in HEK-
293 cells and did not move to the plasma membrane. Since wild-type hMC4R does not 
require co-expression with MRAP1 for trafficking to the plasma membrane, the authors 
concluded that the “stop-transfer” sequence  in the absence of co-expression with human 
MRAP1 in HEK-293 cells preventing trafficking of the chimeric receptor. In their study, 
Fridmanis et al. (2010) did not do the reciprocal experiment and make an hMC4R  N-
terminal /hMC2R chimeric receptor that based on their hypothesis should be able to 
move to the plasma membrane without co-expression with MRAP1.  
        If the “stop transfer sequence” hypothesis is correct, then the chimeric receptor 
xtMC1R N-terminal/hMC2R should also traffic to the plasma membrane in the absence 
of co-expression with MRAP1 in CHO cells, and be activated following stimulation with 
hACTH(1-24).  However, as indicated in Figure 12A and B replacing the N-terminal of 
hMC2R with either xtMC1R N-terminal sequence did not result in activation. A flaw in 
the Fridmanis et al (2010) study was that the authors did not consider the possibility that 
the inability of the hMC2R N-terminal/hMC4R chimeric receptor to traffic to the plasma 
membrane of HEK293 cells might have been due to the miss-folding and degradation of 
the hMC2r/hMC4R chimeric receptor. A re-evaluation of the Fridmanis et al (2010) 




CHAPTER 3: Evaluation of the EC1 Chimeric Receptor 
       The next chimeric receptor tested the exchange of the hMC2R EC1 domain with the 
EC1 domain of xtMC1R. Figure 13 shows the xtMC1REC1/hMC2R chimeric activation 






































Chimeric xtMC1R/hMC2R EC1 co-expressed with mMRAP1
hMC2R + mMRAP1


















Figure 13: xtMC1REC1/hMC2R co-expressed with mMRAP1 and simulated with 
hACTH(1-24). The extracellular 1 domain (EC1) of xtMC1R was replaced with the EC1 
domain of xtMC1R (Figure 11) to make the xtMC1R/hMC2R EC1 chimeric receptor. 
Wild type hMC2R (red dose response curve) and the xtMC1R/hMC2R EC1 chimeric 
receptor (blue does response curve) were separately co-expresssed with mMRAP1 in 
CHO cells as described in Methods. Also, the xtMC1R/hMC2R EC1 chimeric receptor 
was expressed alone (green dose response curve) (n=3).  
Following stimulation with hACTH(1-24), the wild type hMC2R had an EC50 value of 
2.8 x 10-12 M +/- 8.1 x 10-13. When the xtMC2REC1/hMC2R chimeric receptor was co-
expressed with mMRAP1 there was a 10-fold shift in sensitivity to hACTH(1-24); the 
EC50 value for this dose response curve (blue) was 2.4 x 10
-11 M +/- 3.1 x 10-12.  A t-test 
calculated a p-value of 0.0002 indicating that there is statistical difference between the 
xtMC1R/hMC2R EC1 and the wild type hMC2R. These results indicate insertion of the 




xtMC1REC1/hMC2R chimeric receptor as compared to the wild-type hMC2R control. 
The curve shown in green is the xtMC1REC1/hMC2R expressed in the absence of 
mMRAP1 which resulted in no activation. Therefore, exchanging the EC1 domain of 
hMC2R with the EC1 domain of xtMC1R did not make the chimeric receptor MRAP1 
independent.  
 EC1 Cassette Alanine Mutants 
To determine which amino acid positions in the human EC1 have an effect on 
activation, an alanine cassette paradigm was used (Figure 14 &15). The EC1 domain is 
18 amino acids in length (Table 1). Therefore, six mutant receptors were made in the 
hMC2R EC1 domain where each mutant replaced three amino acid residues with three 
alanines; these mutants are presented in Table 1. By only replacing three amino acids at a 
time for each cassette mutant, it might decrease the chances of disrupting the tertiary 












Table 1: hMC2R EC1 Domain Cassette Mutants. This table includes the six cassette 
mutants in the EC1 domain of hMC2R. The red underline denotes where three residues 
were replaced with three alanines.  
Predictions for possible outcomes of the cassette alanine substitution experiments 
are presented in Figure 14. Given the position of the activation motif in MRAP1, the 
amino acid positions in “red” appeared to be the mostly contacts with the activation motif 
of MRAP1. 
After designing these mutant receptors, the EC1 domain cassette mutants were 
tested using an activation assay. The results for the hMC2R EC1 domain AAA1, AAA2, 
AAA3 cassette mutants are shown in Figure 15. For this assay, the mutant receptors were 
separately co-expressed with mMRAP1, and stimulated with hACTH(1-24). The curve 
shown in red is the wild type hMC2R receptor which had an EC50 value of 1.1 x 10
-12 M 
+/- 2.3 x 10-13. The blue curve shows the hMC2R EC1 AAA1 receptor (EC50 value = 1.5 
x 10-9 M +/- 2.3 x 10-10).  
Wild type EC1 hMC2R IILRNMGYLKPRGSFETTA 
Mutant 1 (AAA1) AAARNMGYLKPRGSFETTA 
Mutant 2 (AAA2) ILLAAAGYLKPRGSFETTA 
Mutant 3 (AAA3) IILRNMAAAKPRGSFETTA 
Mutant 4 (AAA4) IILRNMGYLAAAGSFETTA 
Mutant 5 (AAA5) IILRNMGYLKPRAAAETTA 





Figure 14: Predictions for the EC1 Multiple Alanine Substitution Experiment. This 
figure shows the 19 residues in EC1 loop of hMC2R. Based on the position of the 
MRAP1 homodimer, the residues shown in red are most likely to interact with the 
activation motif of MRAP1. Shown in blue are the residues that are less likely to interact 
with the activation motif of MRAP1. Finally, the residues shown in green might interact 
with the HFRW binding site. The (    ) indicates positions E80 in the TM2 region and D104 
in the TM3 region that have been shown to affect activation of the MC2R (Chen et al. 
2007 and Chung et al. 2005).  
This mutant receptor had a 1000-fold drop in sensitivity to stimulation by 
hACTH(1-24) (p = 0.0001; One-Way ANOVA). The green curve shows the hMC2R EC1 
AAA2 receptor which had an EC50 value of 8.6 x 10
-13 M +/- 3.2 x 10-13 (p ≥ 0.99 relative 
to wild-type control; One-Way ANOVA). The black curve shows the hMC2R EC1 
AAA3 receptor which had an EC50 value of 2.2 x 10
-12 M +/- 5.2 x 10-13 (p ≥ 0.99 relative 





Figure 15: hMC2R EC1 Cassette Mutants AAA1, AAA2, and AAA3 co-expressed 
with mMRAP1 and stimulated with hACTH(1-24). The extracellular 1 domain of 
hMC2R was replaced with three different triplicate cassettes of alanine substitutions to 
make the hMC2R AAA1, AAA2, AAA3 mutants (Figure 11). The wild type hMC2R (red 
dose response curve) was separately co-expressed with mMRAP1 in CHO cells as 
described in Methods. The hMC2R EC1 AAA1 (blue dose response curve), hMC2R EC1 
AAA2 (green dose response curve), and hMC2R AAA3 (black dose response curve) 
were each co-expressed with mMRAP1 as described in Methods (n=3) 
 
Next, Figure 16 summarizes the results of the activation assay of the hMC2R EC1 
AAA4, AAA5, and AAA6 receptors. For this assay, each receptor was separately co-
expressed with mMRAP1, and stimulated with hACTH(1-24). The curve shown in red is 
the wild type hMC2R receptor which had an EC50 value of 1.1 x 10
-12 M +/- 2.3 x 10-13. 
The green curve shows the hMC2R EC1 AAA4 receptor. The EC50 value for this mutant 




wild-type hMC2R the p value was 0.8 (One-Way ANOVA). The curve shown in blue is 
the hMC2R EC1 AAA5 receptor which had an EC50 value of 2.5 x 10
-12 M +/- 7.2 x 10-13 
(p = 0.02 as compared to wild-type hMC2R; One-Way ANOVA). The black curve shows 
the hMC2R EC1 AAA6 receptor with an EC50  
 
Figure 16: hMC2R EC1 Cassette Mutants AAA4, AAA5, and AAA6 co-expressed 
with mMRAP1 and stimulated with hACTH(1-24). The extracellular 1 domain of 
hMC2R was replaced with three different triplicate cassettes of alanine substitutions to 
make the hMC2R AAA4, AAA5, AAA6 mutants (Figure 11). The wild type hMC2R (red 
dose response curve) was separately co-expressed with mMRAP1 in CHO cells as 
described in Methods. The hMC2R EC1 AAA1 (blue dose response curve), hMC2R EC1 
AAA2 (green dose response curve), and hMC2R AAA3 (black dose response curve) 




value of 2.5 x 10-12 M +/- 6.3 x 10-13 (p = 0.01 as compared to the wild-type MC2R; One-
Way ANOVA). However, the differences in EC50 values for the positive control and the 
AAA5 and AAA6 mutants were less than 2-fold. While the precision of these assays 
resulted in what appears to be a statistically significant difference in activation, from a 
physiological perspective neither cassette alanine mutant had an effect on activation.     
EC1 Single Alanine Mutants 
From the cassette mutant activation experiments, the only mutant to show any 
effect on activation in the EC1 domain of hMC2R that would be considered 
physiologically significant (Dores and Garcia, 2015) was the AAA1 mutant. Therefore, 
single alanine mutants were made at these three amino acid positions in the EC1 domain: 
I84, I85, and L86 to determine whether one or more of these residues may interfere with 
ACTH activation. Figure 17 illustrates the activation assay results of the single alanine 
mutants at position I84, I85, and L86 in the EC1 domain of hMC2R. For this assay, the wild 
type and single alanine mutant receptors were separately co-expressed with mMRAP1 as 
well as stimulated with hACTH(1-24). The curve shown in red is the wild type hMC2R 
receptor which had an EC50 value of 9.7 x 10
-13 M +/- 2.7 x 10-13. The blue curve shows 
the single alanine mutant at position I84. This mutant had an EC50 value of 1.2 x 10
-9 M 
+/- 1.3 x 10-10 and yield a p value ≤ 0.0001 relative to the wild-type hMC2R (One-Way 
ANOVA). This mutant resulted in a 1000-fold shift in sensitivity to hACTH(1-24) when 
compared to the wild type hMC2R. The green curve shows the single alanine mutant at 
position I85 which had an EC50 of 1.5 x 10-12 M +/- 6.4 x 10-13. When compared to the 




significant change in sensitivity to stimulation by ACTH (p ≥ 0.99; One-Way ANOVA). 
The black curve shows the single alanine mutant at residue L86 which had an EC50 value 
of 1.8 x 10-12 M +/- 6.4 x 10-13. Once again, substitution at this position did not result in a 
statistically significant shift in sensitivity to stimulation by ACTH (p ≥ 0.99; One-Way 
ANOVA). These results indicate that the only single alanine mutant that showed any 
effect on activation was the single alanine mutant at position I84.  
 
Figure 17: hMC2R EC1 single alanine mutants at positions 84,85, and 86 co-
expressed with mMRAP1 and stimulated with hACTH(1-24). Single alanine mutants 
at residue positions I84, I85, and L86 were made in the EC1 domain of hMC2R (Figure 11). 
All receptors in this assay were separately co-expressed with mMRAP1 and stimulated 
with hACTH(1-24) as described in Methods. The curve shown in red is the wild type 
hMC2R. The curve shown in blue is the single alanine mutant at position I84. The curve 
shown in green is the single alanine mutant at position I85. The curve shown in black is 






          In an early study Hinkle et al. (2011) observed that substitution of the entire 
TM2/EC1/TM3 regions of hMC2R with corresponding domains of hMC4R resulted in a 
decrease in activation of the chimeric receptor co-expressed with mMRAP1 following 
stimulation with hACTH(1-24). However, this chimeric receptor/mMRAP1 did traffic to 
the plasma membrane. Since interaction with MRAP1 involves both activation and 
trafficking, the expectation was that trafficking should have blocked by this radical 
substitution of both TM2 and TM3. To clarify the results of Hinkle et al (2011) study, a 
less drastic chimeric receptor was used in Figure 13. In this experiment, only the EC1 
domain of the hMC2R was replaced with the corresponding domain of the xtMC1R. This 
chimeric receptor resulted in a 10-fold shift in sensitivity to ACTH(1-24), but did not 
completely block activation of the chimeric receptor. These results are in agreement with 
the Hinkle et al. (2011) study, and once again suggest that while disruption of EC1 
domain can interfere with activation, this region of hMC2R is most likely not the contact 
site with the activation motif of MRAP1. The next set of experiments in this chapter were 
designed to explain the 10 fold drop in sensitivity to activation by hACTH(1-24) that is 
associated with perturbations of EC1.   
As shown in Figure 14, the most likely sites for interaction between the activation 
motif on the N-terminal of MRAP1 and amino acid positions on EC1 would be between 
N88 and S97.  Surprisingly, the EC1 cassette alanine substitution activation assays did not 
support this hypothesis.  The results showed that there was no significant shift in 




were stimulated with hACTH (1-24) (Figures 15 and 16). In fact, the only receptor that 
showed a shift in sensitivity to hACTH (1-24) stimulation was the EC1 AAA1 (I84I85L86) 
receptor. As shown in Table 1 and Figure 14, the hMC2R EC1 AAA1 receptor is 
positioned at the beginning of EC1 loop, and therefore, right at the surface of the plasma 
membrane of the cell. Since the AAA1 mutant is close to a portion of the HFRW binding 
site on hMC2R (Figure 14), it would appear that alanine substitution at this site has 
interfered with ability of hACTH(1-24) to enter the HFRW binding site. In Figure 18, a 
critical amino acid residue (E80) is shown in the TM2 region of the receptor that is needed 
for activation of the hMC2R (Chen et al. 2007). Because the hMC2R EC1 AAA1 is near 
this residue, it could have interfered with activation of the receptor. In fact single alanine 
substitution at I84I85L86 indicate that only position I84 interfered with stimulation by 
hACTH(1-24) (Figure 17).  
 
Figure 18: The hMC2R TM2, EC1 and TM3 Amino Acid Sequence. The hMC2R 
EC1 domain is shown in its entirety. The hMC2R TM2 and TM3 domains are partially 
included because of the importance of two amino acid residues in these regions. The 
partial TM2 region starts at position I78 while the partial TM3 region stops at residue S108. 
In the hMC2R TM2 region, the amino acid residue, E80, is critical for activation of the 
hMC2R. This amino acid residue is depicted by a yellow star. In the hMC2R TM3 
region, the amino acid, D103, is critical for activation of the receptor as well. This amino 
acid residue is depicted by a green plus sign. Both of these amino acids are found in the 
HFRW binding pocket of the receptor (Chen et al., 2007). 
 
Furthermore, Figure 18 shows another important amino acid, D103, which is part 




the hMC2R EC1 AAA6 mutant is in close proximity to this amino acid residue. 
However, the hMC2R EC1 AAA6 mutant receptor resulted in only a 2-fold drop in 
activation.  That said, activation of hMC2R can be adversely affected by substitution at 
D104 (Chung et al. 2005). It would appear that substitutions to the C-terminal side of 
either E80 or D103 can have adverse effects on activation.    In conclusion, these results 
provide evidence that the single alanine mutant I84 is affecting the activation of the 
receptor, but contact between this residue and the activation motif of MRAP1 is highly 







CHAPTER 4: Evaluation of the EC3 Chimeric Receptor 
 Having eliminated the N-terminal domain and EC1 as the contact site for 
MRAP1, the next extracellular loop that was evaluated was EC3. In the next set of 
chimeric receptor experiments the EC3 domain of hMC2R was replaced with the EC3 
domain of xtMC1R (Figure 11). Figure 17A and B illustrates the results of the chimeric 
xtMC1REC3/hMC2R activation assay. In Figure 17A, the curve shown in red is the 
wildtype hMC2R co-expressed with mMRAP1 (positive control) and the EC50 value was 
4.0 x 10-12 M +/- 9.2 x 10-13. Next, the chimeric xtMC1REC3/hMC2R receptor was co-
expressed with mMRAP1 and is shown as the blue curve. Following stimulation with 
hACTH(1-24), the results show that there was no activation of this chimeric receptor. 
These results appear to coincide with an earlier chimeric study where the TM6/EC3/TM7 
domain of hMC2R was exchanged with the TM6/EC3/TM7 domain of hMC4R (Hinkle 
et al., 2010).  In the Hinkle et al. study, this substitution caused complete loss of surface 
expression and activation of the hMC4R/hMC2R chimeric receptor. However, this drastic 
substitution of these three domains could have interfered with the HFRW binding site on 
hMC2R (Chen et al., 2007) as well as proper folding for the hMC2R to be trafficked to 
the plasma membrane. Shown in the green curve, the chimeric xtMC1REC3/hMC2R 
receptor when expressed alone resulted in no activation after stimulation with hACTH(1-




with the EC3 domain of xtMC1R does not make this chimeric receptor MRAP1 
independent.  
 Although these chimeric receptor results suggest that the EC3 domain plays an 
important role in activation of the receptor, past studies have shown that there are critical 
amino acid residues located in the EC3 domain that are required for proper protein 
folding of the hMC2R. In 2007, Yang et. al. showed that there are three cysteines that are 
involved in disulfide bridge formation at positions C246, C252, and C254 (Figure 11). When 
looking at the EC3 domain of xtMC1R (Figure 11), this receptor contains only two of 
these critical residues which are located  at positions C261 and C267 (Figure 11). Since the 
EC3 domain of xtMC1R lacks the third cysteine residue, a new chimeric receptor was 
designed in which the EC3 domain of the hMC2R was replaced with the a modified EC3 
domain of xtMC1R in which position S270 was replace with a cysteine residue. Figure 
17B illustrates the results of the new chimeric xtMC1REC3/hMC2R receptor. The curve 
shown in red is the wild type hMC2R co-expressed with mMRAP1 and the EC50 value 
was 4.0 x 10-12 M +/- 9.2 x 10-13 when stimulated with hACTH(1-24). The curve shown 
in blue is the new chimeric xtMC1REC3/hMC2R chimeric receptor with cysteine at 
position C270 co-expressed with mMRAP1. Following stimulation of this chimeric 
receptor resulted in a 100-fold shift in sensitivity to hACTH(1-24) when compared to the 
wild type hMC2R control. The chimeric receptor had an EC50 of 1.9 x 10
-10 M +/- 2.8 x 
10-11, and a t-test showed this shift to be statistically significant (p = 0.001). The curve 
shown in green is the chimeric xtMC1REC3/hMC2R with C270 expressed alone and 




hMC2R with the corresponding domain of xtMC1R did not make the chimeric receptor 
MRAP independent.  
A. B.  
Figure 19: Analysis of the xtMC1REC3/hMC2R chimeric receptors. A) The EC3 
domain of hMC2R was replaced with the EC3 domain of xtMC1R (Figure 11) to make 
the xtMC1REC3/hMC2R chimeric receptor. Wild-type hMC2R (red dose response 
curve) and the chimeric xtMC1R/hMC2R (blue dose response curve) were separately co-
expressed with mMRAP1 in CHO cells as described in Methods. The chimeric 
xtMC1REC3/hMC2R receptor was also expressed alone (green does response 
curve)(n=3). B) A second chimeric xtMC1REC3/hMC2R receptor was made in which 
the S270 (xtMC1R; Figure 11) was replaced with C270. Wild type hMC2R (red dose 
response curve) and the chimeric xtMC1REC3/hMC2R with C270 (blue does response 
curve) were separately co-expressed with mMRAP1 in CHO cells as described in 
Methods. The chimeric xtMC1REC3/hMC2R with C270 was also expressed alone (green 
dose response curve) (n= 3).  
 
hMC2R EC3 Single and Double Alanine Mutants 
 To determine which amino acid positions effect activation in the EC3 domain of 
hMC2R, a single alanine substitution approach was utilized in the next set of 
experiments. There are a few observations that led to the use of single site directed 




critical for successful disulfide bridge formation as reported by Yang et al. (2007). A 
concern for this portion of the study was that breaking any of these three disulfide bridges 
would result in a change in the shape of the receptor that would disrupt activation. Hence, 
the objective in this set of experiments was to minimize interference with the cysteine 
residues in EC3 to hopefully avoid disruption of disulfide bond formation. One approach 
would be to use a single alanine substitution paradigm to hopefully minimize disruption 
of disulfide bond formation. In addition, the operating assumption was that the positions 
to investigate in the EC3 domain should be positions that differ between xtMC1R EC3 
and hMC2R EC3. As shown in Figure 11, position P262 and position Y270 are identical in 
xtMC1R and hMC2R. Excluding substitution at the three cysteine residues, there are six 
positions in the EC3 domain that would be appropriate for single alanine substitution: 
S248, N249, P250, Y251, M256, and S257 (Table 2).  
Table 2: hMC2R EC3 Domain Single Alanine Mutants. This table includes the six 
single alanine mutants in the EC3 domain of hMC2R. The important cysteine residues are 
denoted in red while the positions that were substituted with alanines are denoted in green 
and underline. 
Wild type hMC2R EC3 Domain CPSNPYCACYMS 
Mutant 1  CPANPYCACYMS 
Mutant 2  CPSAPYCACYMS 
Mutant 3  CPSNAYCACYMS 
Mutant 4  CPSNPACACYMS 
Mutant 5  CPSNPYCACYAS 




Figure 18 illustrates the activation assay of the first three single alanine mutants in 
which   positions S248, N249, and P250 were individually replaced with an alanine residue 
(Table 2). The wild type hMC2R receptor and each hMC2R single-alanine mutant 
receptor was separately co-expressed with mouse MRAP1 and stimulated with 
hACTH(1-24).  
 
Figure 20: hMC2R EC3 single alanine mutants at residues S248, N249, and P250 co-
expressed with mMRAP1 and stimulated with hACTH(1-24). The wild type hMC2R 
and the three mutant receptors were separately co-expressed with mMRAP1 and 
stimulated with hACTH(1-24) as described in Methods. The curve shown in red is the 
wild type hMC2R. The curve shown in blue is the single alanine mutant at position S248 
(M1 = Mutant 1) The curve shown in green is the single alanine mutant at position N249 
(M2 = Mutant 2)The curve shown in black is the single alanine mutant at position P250 




The wild type hMC2R receptor is shown in red and the EC50 value was 2.8 x 10
-12 
M +/- 7.6 x 10-13. The curve shown in blue is the first single-alanine mutant (S248/A248). 
For this mutant receptor the EC50 value was  3.5 x 10
-12 M +/- 7.2 x 1013 (p = 0.99; One-
Way ANOVA). The curve shown in green is the second single alanine mutant 
(N249/A249). This mutant receptor had an EC50 value of 2.3 x 10
-12 M +/- 4.7 x 10-13 (p= 
0.42; One-Way ANOVA). The curve shown in black is the third single alanine mutant 
P250/A250). This mutant receptor had an EC50 value of 3.7 x 10
-12 M +/- 2.1 x 10-13  
 
Figure 21: hMC2R EC3 single alanine mutants at residues Y251, M256, and S257 co-
expressed with mMRAP1 and stimulated with hACTH(1-24). The wild type hMC2R 
and the three mutant receptors were separately co-expressed with mMRAP1 and 
stimulated with hACTH(1-24) as described in Methods. The curve shown in red is the 





In summary, the single alanine mutants at residues S248, N249, and P250 in the EC3 domain 
of the hMC2R had no effect, either positive or negative on activation of hMC2R 
following stimulation with hACTH(1-24).   
Figure 19 illustrates the activation assay of the next three single alanine mutants 
in the EC3 domain of hMC2R at positions Y251, M256, and S257 (Table 2). The wild type 
hMC2R and each mutant receptor was separately co-expressed with mMRAP1 and 
stimulated with hACTH(1-24). The curve shown in red is the wild type hMC2R receptor 
that had an EC50 value of  2.8 x 10
-12 M +/- 7.6 x 10-13. The curve shown in blue is the 
fourth mutant where an alanine replaced residue Y251 in the EC3 domain of hMC2R. This 
mutant had an EC50 value of 3.2 x 10
-11 M +/- 7.2 x 10-12 (p = 0.98; One-Way ANOVA). 
The curve shown in blue is the fifth mutant where an alanine replaced residue M256 in the 
EC3 domain of hMC2R. This mutant had an EC50 value of 2.9 x 10
-11 M +/- 9.5 x 10-12 (p 
= 0.93; One-Way ANOVA). The curve shown in black is the sixth mutant where an 
alanine replaced residue S257 in the EC3 domain of hMC2R. This mutant had EC50 value 
of 2.1 x 10-11 M +/- 7.2 x 10-12 (p = 0.98; One-Way ANOVA). When compared to the 
wild type hMC2R, each of the hMC2R EC3 single alanine mutants at positions Y251, 
M256, and S257 resulted in little to no difference in activation. These results were 
perplexing. The operating hypothesis was that residues in the extracellular loop near the 
apex of the loop would interact with the activation motif of MRAP1 (Figure 20). Hence, 
it was assumed that one or more of the single-alanine mutants would interfere with 




EC3, none of these single-alanine mutations appear to be involved with the contact site 
for MRAP1.    
Figure 22: Predictions for the EC3 Single and Double Alanine Substitution 
Experiment. This figure shows the 12 residues in the EC3 extracellular loop of 
hMC2R. Based on the position of the MRAP1 homodimer, the residues shown in red are 
most likely to interact with the activation motif of MRAP1. Shown in blue are the 
residues that are less likely to interact with the activation motif of MRAP1. Finally, the 
residues shown in green denote the important cysteines. Note the internal disulfide 
bridge. The third cysteine in EC3 forms a disulfide bridge with the cysteine residue 
located in the N-terminal of hMC2R (Yang et al., 2007).  
 
Perhaps by inserting multiple alanine substitutions in EC3, it might be possible to 
interfere with activation. To achieve this end, a double alanine substitution experiments 
were done (Figure 21). In this experiment, two separate double alanine mutants were 
made to see if an increase in the number of alanines might adversely affect activation by 
hACTH(1-24)). A double alanine mutant was made at residues S248 and N249 (Mutant 2) 




that these double alanine substitution mutants were made without replacing any of the 
cysteines in an effort to avoid disrupting disulfide bridge formation (Table 3). 
Wild type hMC2R EC3 Domain CPSNPYCACYMS 
Double Alanine Mutant 2 (M2) CPAAPYCACYMS 
Double Alanine Mutant 3 (M3) CPSNAACACYMS 
Table 3: hMC2R EC3 Domain Double Alanine Mutants. This table includes the two 
double alanine mutants in the EC3 domain of the hMC2R. The important cysteine 
residues are denoted in red while the positions that were substituted with alanine are 
denoted in blue and underline.  
 
Figure 21 illustrates the hMC2R EC3 domain double alanine substitution 
activation assay (Table 3). The wild type hMC2R and each double mutant receptor was 
separately co-expressed with mMRAP1 and stimulated with hACTH(1-24). The curve 
show in red is the wild type hMC2R and the EC50 value was 3.6 x 10
-12 M +/- 9.5 x 10-12. 
The curve shown in blue is the first double mutant, Mutant 2 (S248 N249/A248A249). This 
double mutant had an EC50 value of 5.7 x 10
-12 M +/- 9.5 x 10-13 (p= 0.99; One-Way 
ANOVA). The curve shown in green is the second double mutant, Mutant 3 (P250 
Y251/A250A251). This double mutant had an EC50 of 1.2 x 10
-12 M +/- 2.2 x 10-12 (p = 0.67; 
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Figure 23: hMC2R EC3 double alanine mutants M2 and M3 co-expressed with 
mMRAP1 and stimulated with hACTH(1-24). The wild type receptor hMC2R receptor 
as well as double alalnine mutants M2 and M3 were separately co-expressed with 
mMRAP1 and stimulated with hACTH(1-24) as described in Methods. The curve shown 
in red is the wild type hMC2R. The curve shown in blue is the double alanine mutant, 
Mutant 2 (M2), at positions S249 and N250. The curve shown in green is the EC3 double 
alanine mutant, Mutant 3 (M3), at positions P250 and Y251 (n = 3) 
 
Conclusions  
Overall, the operating premise of this thesis is based on the study by Malik et al. 
(2015); this study’s results indicated that one of the EC domains of hMC2R must be 
making contact with the activation motif of MRAP1 that is positioned on the extracellular 




eliminated from consideration in Chapters 2 and 3, this chapter has focused on the EC3 
domain. However, the single and double alanine mutants of the hMC2R EC3 domain did 
not disrupt activation of these mutant receptors when co-expressed with mMRAP1. 
Hence, it was not possible to show that MRAP1 is interacting with the EC3 domain of 
hMC2R. As a result, it would appear that the chimeric xtMC1REC3/hMC2R receptor 
(Figure 19) must have misfolded in some way which caused a drop in sensitivity to 
hACTH(1-24) rather than an interference with an interaction with MRAP1. That said, the 
chimeric hMC2R/hMC4R experiments conducted by Hinkle et al. (2011) in which the 
TM6/EC3/TM7 region of hMC2R was replaced with the corresponding region of hMC4R 
must have also caused an unexpected distortion of the 3-D shape of the chimeric receptor. 
Since disrupting the disulfide bridges associated with the EC3 appears to the only way to 
block activation of hMC2R (Yang et al., 2007), there is not sufficient evidence to support 
the assumption that the EC3 domain is not the contact site for MRAP1.  
        In retrospect, interaction between the TM6/EC3/TM7 domain of hMC2R and 
MRAP1 seems rather unlikely. Yang et al., (2007) had already shown that the proper 
disulfide bridge formation between EC3 and the N-terminal of hMC2R was essential for 
activation. In the current study this point was made very clear in Figure 12A (N-terminal 
chimeric receptor that lacked a cysteine residue), and Figure 19A (EC3 chimeric receptor 
that lacked a cysteine residue at position 265). In addition the single alanine substitution 
experiments for the EC3 domain of hMC2R indicated no adverse effect on activation 
(Figures 20 and 21). The rationale for the chimeric receptor experiments using xtMC1R 




difference in amino acid positions between xtMC1R and hMC2R should help identify the 
possible sites in hMC2R that could be interacting with the activation motif of MRAP1 
(activation function) and the TM of MRAP1 (trafficking function). However as shown in 
Figure 24, there is considerable primary sequence identity with the TM6/EC3/TM7 
domains of xtMC1R and hMC2R. For the TM6 domain, the primary sequence identity is 
76% (positions highlighted in red). However, when neutral substitutions are considered, 
the sequence similarity is 88%. Hence, TM6, a portion of the HFRW binding site, would 
appear to be an unlikely contact site for the TM of MRAP1. The single-alanine 
substitution experiments of EC3 domain eliminated the possibility that the activation 
motif of MRAP1 is interacting with this domain. Likewise, the sequence identity between 
xtMC1R and hMC2R for the EC3 domain is 64%, and the sequence similarity between 
these two domains is 86%. Hence, interaction between hMC2R and MRAP1 at these 
domains seems highly unlikely.          
         [--------------TM6----------]     EC3    [-----TM7-------------] 
hMC2 KGAITLTILLGVFIFCWAPFVLHVLLMTFCPSNPYCACYMSLFQVNGMLIMCNAVIDPFIYAFR               
xMC1 KGAITLTLLLGVFFLCWGPLFLHLTLFVSCPGHHICNSYFYYFNIYLLLVICNSVIDPLIYAFR 
Figure 24: Alignment of the TM6/EC3/TM7 domain of hMC2R and xtMC1R. The 
TM^/EC3/TM7 domains of xtMC1R and hMC2R were aligned in Figure 11. Positions 
highlighted in red were identical. Positions highlighted in green represent neutral 






CHAPTER 5: Evaluation of the EC2 Chimeric Receptor – Testing Hypothesis 2 
Human MC2R has by far the most complicated activation mechanism of the five 
human melanocortin receptors (Dores, 2018). As discussed in the INTRODUCTION, 
Schwyzer (1977) observed that the mammalian “ACTH” receptor (aka MC2R) could 
only be activated by ACTH(1-39), but not by α-MSH [N-acetyl-ACTH(1-13)NH2], and 
within the sequence of ACTH(1-39) there were two amino acid motifs (H6F7R8W9 & 
K15K16R17R18) that are required for activation of the “ACTH” receptor. The cloning and 
sequencing of hMC2R confirmed the unique ligand selectivity of the “ACTH” receptor 
(Mountjoy et al., 1992). The studies of Pogosheva et al. (2005) on hMC4R and Chen et 
al. (2007) on hMC2R identified critical amino acid positions in TM2, TM3, TM6, and 
TM7 located close to the surface of the plasma membrane as the binding site for the 
HFRW motif. Analysis of the amino acid sequences of melanocortin receptors from bony 
fishes, a cartilaginous fish, an amphibian, a reptile, a bird, and mammals indicated that 
these amino acid positions in TM2, TM3, TM6, and TM7 have been rigorously conserved 
during the radiation of the gnathostomes (Dores, 2009; Baron et al., 2009). In addition, 
the Chen et al. (2007) study indicated that F168 in EC2 may be at the KKRR binding site 
of hMC2R, and F178 in TM5 is required for the activation of the receptor, and this 
conclusion was confirmed by the single alanine substitution paradigm used our lab 




human mutation at H170 in EC2 that resulted in Familial Glucocorticoid Deficiency Type 
I (FGD-1). The H170 mutation while inhibiting activation of MC2R did not interfere with 
trafficking of the mutant receptor to the plasma membrane (Chung et al., 2008). Finally, 
the Malik et al (2015) study revealed that the activation motif in the N-terminal of 
MRAP1 made contact with one of the extracellular domains of MC2R to facilitate 
activation of the receptor. The objective, then, of this study has been to identify that 
extracellular domain. Chapters 2, 3, and 4, tested Hypothesis 1 that MRAP1 was making 
contact with hMC2R at either the N-terminal domain, the EC1 domain, or the EC3 
domain to facilitate activation. The operating premise was that contact with any of these 
three extracellular domains would place the KKRR binding site (EC2) of the receptor in a 
conformation such that ACTH could bind to the receptor and initiate the two-step 
activation process presented in Figure 8 (Dores, 2018). However, the results of the 
chimeric receptor and alanine-substitution experiments presented in Chapters 2, 3, and 4 
do not support Hypothesis 1. Hence, this chapter of the thesis will address Hypothesis 2: 
the contact site between MRAP1 and hMC2R occurs at extracellular loop 2 (EC2).  
         As indicated in Figure 11, the EC2 domain of xtMC1R and hMC2R had not 
primary sequence identity, hence a chimeric receptor paradigm was a reasonable 
approach to initially test Hypothesis 2. Analysis of the xtMC1REC2/hMC2 chimeric 
receptor is shown in Figure 25. The dose response curve shown in red is the wild-type 
hMC2R co-expressed with mMRAP1 which had an EC50 value of 1.1 x 10
-11 M +/- 1.5 x 
10-12. The curve shown in blue is the xtMC1REC2/hMC2R chimeric receptor co-
expressed with mMRAP1 which had an EC50 value of 2.2 x 10




chimeric EC2 receptor was nearly 1000 less sensitive to stimulation by hACTH(1-24) as 
compared to the wild-type hMC2R ( p<0.001). In addition, this level of suppression of 
activation for the EC2 chimeric receptor far exceeded the results observed for the N-
terminal chimeric receptor (Figure 12), the EC1 chimeric receptor (Figure 15), or the 
EC3 chimeric receptor (Figure 17).  The negative control for this experiment was to 
express the xtMC1REC2/hMC2R EC2 chimeric receptor alone, and this curve is shown 
in green. The negative control resulted in no activation; clearly showing that the 
xtMC1REC2/hMC2R chimeric receptor is not MRAP1 independent.  
  
Figure 25: xtMC1REC2/hMC2R co-expressed with mMRAP1 and simulated with 
hACTH(1-24). The extracellular 2 domain (EC2) of xtMC1R was replaced with the EC2 
domain of xtMC1R (Figure 11) to make the xtMC1REC2/hMC2R chimeric receptor. 
Wild type hMC2R (red dose response curve) and the xtMC1R/hMC2R EC2 chimeric 
receptor (blue does response curve) were separately co-expressed with mMRAP1 in CHO 
cells as described in Methods. Also, the xtMC1REC2/hMC2R chimeric receptor was 




The operating assumption for the results observed for Figure 25 was that 
substitution of the xtMC1R EC2 domain has disrupted the KKRR binding site of 
hMC2R, thus inhibiting activation of the chimeric receptor by hACTH(1-24). Since 
xtMC1R can be activated by NDP-MSH, it is conceivable that the chimeric 
xtMC1REC2/hMC2R receptor might respond to stimulation by NDP-MSH. To test this 
hypothesis, the xtMC1REC2/hMC2R chimeric receptor was co-expressed with 
mMRAP1 and stimulated with NDP-MSH (Figure 26). For this experiment, two controls 
were used. The wild-type hMC2R receptor was co-expressed with mMRAP1 and 
stimulated with hACTH(1-24) to show that the cAMP/reporter gene assay worked in this 
experiment. The second control involved expressing the wild-type hMC2R co-expressed 
with mMRAP1, and to stimulate with NDP-MSH. As shown in Figure 26, following 
stimulation with hACTH(1-24), the wild type receptor (red curve) was activated by 
hACTH(1-24) and had an EC50 value of 8.5 x 10
-12 M +/- 1.4 x 10-12. The blue curve 
shows the wild-type hMC2R co-expressed with mMRAP1 stimulated with NDP-MSH. 
No activation was observed at concentrations of NDP-MSH from 10-12M to 10-8M. There 
was a minimal increase in stimulation at 10-7 M. When compared to the positive control, 
there is an 84.5% decrease in activation when hMC2R is stimulated with 10-7M NDP-
MSH as compared to the corresponding concentration of hACTH(1-24). This level of 
stimulation is marginally above background. Finally, the green curve shows the 
xtMC1REC2/hMC2R chimeric receptor co-expressed with mMRAP1and stimulated with 
NDP-MSH. There was no stimulation of the chimeric receptor at any of the 




with the corresponding EC2 domain of xtMC1R did not alter the structure of the chimeric 














Figure 26: xtMC1REC2/hMC2R co-expressed with mMRAP1 and stimulated with 
hACTH(1-24) or NDP-MSH. The extracellular 2 domain (EC2) of xtMC1R was 
replaced with the EC2 domain of xtMC1R (Figure 11) to make the xtMC1REC2/hMC2R 
chimeric receptor. Wild type hMC2R (red/blue response curves) and the 
xtMC1REC2/hMC2R chimeric receptor (green does response curve) were separately co-
expressed with mMRAP1 in CHO cells as described in Methods. In this activation assay, 
the wild type hMC2R (red/blue dose response curves) was stimulated with hACTH(1-24) 
or NDP-MSH. The xtMC1REC2/hMC2R chimeric receptor (green dose response curve) 
was stimulated with NDP-MSH. (n=3). 
 
Earlier studies had shown that alanine substitution at F168 in the EC2 domain 
(Chen et al., 2007) or at H170 in the EC2 domain (Dores et al., 2016) interfered with the 



















































these sites played a role in trafficking, the F168/A hMC2R mutant receptor, and the 
H170/A170 hMC2R mutant receptor were analyzed using a cell surface ELISA assay. In 
this experiment the wild-type hMC2R, and the two alanine-substituted mutants of 
hMC2R were co-expressed with mMRAP1.  As shown in Figure 27, alanine substitution 
at the H170 position did not decrease the trafficking of the mutant receptor to the plasma 
membrane as compared to the wild-type hMC2R control (p = 0.27).  However, alanine 
substitution at F168 did lower trafficking of the mutant receptor to the plasma membrane 
as compared to the wild-type hMC2R (p < 0.001).  
 
Figure 27: Cell Surface ELISA analysis of F168/A168 hMC2R and the 
H170/A170hMC2R. This figure illustrates the surface expression of two single alanine 
mutants in the EC2 domain of hMC2R. These mutants include alanine substitution at 
F168/A168 and H170/A170. Each of these mutants was co-expressed with mMRAP1. The 
positive control is the wild type hMC2R co-expressed with mMRAP1 while the negative 
control is the wild type hMC2R expressed alone. One-way ANOVA analysis for positive 






























         The primary objective of this study was to identify the extracellular loop on hMC2R 
that is making contact with the activation motif in the N-terminal of MRAP1. The results 
from Figure 25 point to extracellular loop 2 (EC2) as that contact point. Substituting the 
EC2 domain of xtMC1R into hMC2R resulted in a significant drop in sensitivity of the 
receptor for stimulation by hACTH(1-24) which far exceeded the chimeric experiments 
for the N-terminal domain, EC1 domain or EC3 domain (Figures 12, 15, and 17). This 
result is in agreement with the decline in activation observed when residues in the EC2 
domain were replaced with alanines (Chen et al., 2007; Dores et al., 2016), and the 
spontaneous mutation observed in a human patient at H170 in the EC2 domain (Chung et 
al., 2008). When the observations from Figure 25 and 27 are combined, the most 
parsimonious explanation for the MC2R/MRAP1 interaction is that the N-terminal 
domain of the MRAP1 homodimer that faces the extracellular space, together with H170 
position in EC2 form a binding pocket for the K15K16R17R18 motif of hACTH(1-24). This 
conclusion is shown graphically in Figure 28. In addition, the results of the cell surface 
ELISA analysis (Figure 27) indicate that residue F168 in the EC2 domain plays a role in 
the trafficking of hMC2R by presumably interacting with the transmembrane domain of 
MRAP1 (Sebag and Hinkle, 2009).  
        Partial support for the preceding conclusions comes from a previous study by Sebag 
and Hinkle (2009). The results of that study are summarized in Figure 29A. Sebag and 
Hinkle observed that when the four amino acid activation motif in the N-terminal of 




of 125I-ACTH(1-39) to hMC2R. The outcome of the Sebag and Hinkle (2009) study could 
be explained by two mutually exclusive hypotheses; either the MRAP1 homodimer 
makes contact with hMC2R at the KKRR binding site, or the MRAP1 homodimer make 
contact at some other site on hMC2R and the outcome of that interaction placed the 
KKRR contact site on hMC2R in the proper conformation to allow ACTH to binding to 
hMC2R.  The Sebag and Hinkle (2009) experiment could not distinguish between these 
two possibilities. However, the EC2 chimeric receptor experiment summarized in Figure 
29B is the reciprocal experiment to the Sebag and Hinkle (2009) study. When the wild-
type mMRAP1 was co-expressed with the EC2 Chimeric hMC2R there was a significant 
drop in activation of the EC2 chimeric receptor.  Collectively, these two experiments 
point to an intimate interaction between MRAP1 and hMC2R. The interaction is most 
likely creating a binding site for the KKRR motif of ACTH the would be required to 
initiate the predicted two-step activation mechanism  of hMC2R, and this interaction with 











Figure 28: Modeling the interaction between the EC2 domain of hMC2R and 
theactivation motif of MRAP1. As mentioned in the text, the N-terminal domain of the 
MRAP1 homodimer that faces the extracellular space contains the activation motif that 
may interact with position H170 in the EC2 domain of hMC2R to create binding pocket 
for the K15K16R17R18 motif of hACTH(1-24). Note (----) that indicated interaction 
between EC2 amino acid residue and activation motif of MRAP1. Also, this model 
includes the position, F168, located in the EC2 domain. Cell Surface ELISA results in 
Figure 27 suggest that residue F168 may play a role in trafficking due to a significant drop 
in surface expression. Therefore, this residue may interact with the transmembrane 
domain of the hMC2R. Note the (----) that indicates an interaction between the EC2 






Figure 29: A) This figure summarizes the study of Sebag and Hinkle (2009). In brief, 
co-expression of mutant form of mMRAP1 (alanine substitution at the activation motif) 
and wild-type hMC2R resulted in a significant drop in the binding of 125I-ACTH(1-39). 
B) This figure summarizes the outcome of Figure 25. Co-expression of wild-type 
mMRAP1 with the xtMC1REC2/hMC2R chimeric receptor resulted in a significant drop 
in activation of the receptor following stimulation with hACTH(1-24).          
 
         A survey of the literature indicates that at least one other group proposed that the 
EC2 domain and MRAP1 form the binding site for the KKRR motif of ACTH (Fridmanis 
et al., 2010). In this study a confocal imaging procedure was used to evaluate interactions 
between mMRAP1 and various chimeric receptors of hMC2R and hMC4R. This novel 
procedure was combined with hormone/receptor binding studies, and the results of that 
study are summarized in Figure 30. However, the Fridmanis et al (2009) does raise some 
concerns with respect to the conclusions that were drawn for this study, as indicated in 





Figure 30: Summary of the conclusions presented in Fridmanis et al., 2010. In this 
study the authors propose that two MRAP1 homodimers interact with hMC2R. The 
authors propose that MRAP1 contact at TMIII interferes with the HFRW binding domain 
in the receptor. In addition, MRAP1 also makes contact with TM4/EC2 domain to form 
the KKRR binding site. The stoichiometry presented in this figure does not agree with the 
study of Cooray et al., 2010 which used FRET imaging analysis to show that one hMC2R 
monomer and one MRAP1 monomer form a heterodimer.   
 
        Although the experimental data to support the Fridmanis et al (2010) conclusions is 
not strong, the current study in combination with the Sebag and Hinkle (2009), the Chen 
et al (2007) study, and the Chung et al (2008) all point to the N-terminal terminal of 
MRAP1 making contact with the EC2 domain of hMC2R, and that interaction appears to 




       Given these conclusions, the next issue to resolve was the role that F178 in the TM5 
domain plays in the activation process. Alanine substitution at this amino acid position 
greatly reduced activation (Dores et al., 2016). However, given the location of this 
residue relative to F168 and H170, it would be difficult to imagine that F178 is also in the 
KKRR  binding site. However, F178 may have a role in the trafficking of hMC2R to the 





CHAPTER 6: Evaluating the role of TM4 and TM5 in the trafficking of hMC2R 
       Since aligning xtMC1R and hMC2R to identify regions within domains that are 
clearly distinct between the two receptors proved useful in identifying the EC2 domain of 
hMC2R as the putative contact site for the N-terminal of MRAP1, a similar strategy was 
employed to evaluate residues in the TM4 and TM5 domains of hMC2R that may be 
interacting with the TM of MRAP1 to facilitate trafficking. As noted in Figure 10B, 
mMRAP1 did not affect the trafficking of xtMC1R in either a positive or negative 
manner. Hence, the operating assumption for designing the next set off experiments was 
that regions in either TM4 or TM5 of xtMC1R and hMC2R that are conserved, are less 
likely to be the contact site for the TM of mMRAP1 than regions that are variable in the 
two receptors. As shown in Figure 31, for TM4 the primary sequence identity between 
R146 and T162 is 35% and the primary sequence similarity was 66%. Between G163 and I167 
there was no primary sequence identity, but the sequence similarity was 60%. For TM5 
the primary sequence identity between L184 and F197 was 50%, and the primary sequence 
similarity was 93%; whereas between T178 and P183 the primary sequence identity was 
14% and the primary sequence similarity was 71%. Based on these observations, single 




to P183) were made and analyzed using a cell surface ELISA protocol to determine 
whether TM4 or TM5 is involved in the trafficking of hMC2R to the plasma membrane.   
   [-------TM4-----------]       [-------TM5---------]  
h  RRTVVVLTVIWTFCTGTGITMVI 167   TFTSLFPLMLVFILCLYVHMF 197 
xt RRVVIAIGVIWSVSLVCAAIFIV 172   CLIVFFLFMLALMVALYIHMF 202 
 
Figure 31: Alignment of xtMC1R (xt) and hMC2R (h) TM4 and TM5. Positions that 
were identical in these two domains are highlighted in red.  
As shown in Figure 32, alanine-substitution at G162 and T164 had no effect on the 
trafficking of the alanine-substituted G162/A162 or the T164/A164 hMC2R receptors. 
However, alanine-substitution at I163 resulted in a statistically significant decline in the 
trafficking of the I163/A163 hMC2R to the plasma membrane (p = 0.01).        
        
Figure 32: Cell Surface ELISA of TM4 Single Alanine Mutants of hMC2R. This 
figure illustrates the results of surface expression of the single-alanine mutants at 
positions G162/A162, I163/A163, and T164/A164. All TM4 alanine mutants were co-expressed 
with mMRAP1. The positive control is wild type hMC2R co-expressed with mMRAP1. 
The negative control is hMC2R alone. One-way ANOVA analysis for positive control vs. 
negative control was p = 0.007. (n = 3).  
         The remainder of the residues in TM4 is analyzed in Figure 33.  Note that alanine 




























alanine-substituted hMC2 receptors to the plasma membrane. However, trafficking to the 
plasma membrane of the M165/A165 hMC2R mutant was less relative to the positive 
control (p = 0.05). 
          
Figure 33: Cell Surface ELISA of TM4 Single Alanine Mutants of hMC2R. This 
figure illustrates the results of surface expression of the single-alanine mutants at 
positions M165/A165, V166/A166, and I167/A167. All TM4 alanine mutants were co-expressed 
with mMRAP1. The positive control is wild type hMC2R co-expressed with mMRAP1. 
The negative control is the hMC2R expressed alone. One-way ANOVA analysis for 
positive control vs. negative control was p = 0.004. (n = 3). 
 
        The same analysis was done for the TM5 domain (T178 to P183) of hMC2R (Figure 
34). The T177/A177, T179/A179, S180/A180, and P183/A183 mutant forms of hMC2R trafficked 
to the plasma membrane as well as the wild-type hMC2R control. However, there was a 
significant decline in the trafficking of the F178/A178 mutant (p = 0.002),  the L181/A181 































A.      
B.  
Figure 34: Cell Surface ELISA of TM5 Single Alanine Mutants of hMC2R. This 
figure illustrates the results of surface expression of the single-alanine mutants at 
positions T177/A177, F178/A178, and T179/A179, S180/A180, L181/A181, F182/A182, and P183/A183.  
All TM5 alanine mutants were co-expressed with mMRAP1. The positive control is wild 
type hMC2R co-expressed with mMRAP1. The negative control is the hMC2R expressed 
alone. One-way ANOVA analysis for positive control vs. negative control was p = 0.001. 
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       An earlier study indicated that alanine substitution in the G163 to I167 domain of TM4 
had a minimal effect on activation of the receptor following stimulation with hACTH(1-
24); whereas alanine substitution in the T178 to P183 domain of TM5 significantly 
interfered with activation of the alanine-substituted hMC2 receptors (Dores et al., 2016). 
Hence the operating assumption prior to attempting the cell surface ELISA analysis was 
that the TM4 domain may not be involved in trafficking, while the TM5 domain should 
be playing a prominent role in the trafficking of hMC2R to the plasma membrane as a 
result of the interaction with mMRAP1. As shown in Figures 32, 33, and 34, it appears 
the interactions with the TM of mMRAP1 are more complex than anticipated. First, it is 
important to point out that the single-alanine substitution experiments assume that the 
cDNAs for all of the mutant hMC2Rs are expressed at the same level in CHO cells. 
While this assumption is made for all of the experiments presented in this thesis, 
confirmation by real-time PCR analysis or Western Blot analysis would resolve this 
issue. This discussion will proceed based on the assumption that all mutant forms of 
hMC2R express in CHO cells at the same level as the wild-type mMC2R. Given this 



























Figure 35: Modeling the complex interaction between the TM4/EC2/TM5 region of 
hMC2R with the activation motif and TM region of MRAP1. This figure illustrates 
plausible interactions between the TM4/EC2/TM5 domain of the hMC2R with the 
activation motif positioned on the extracellular side as well as the transmembrane domain 
of MRAP1. In Figure 28, it was discussed that due to the interaction with MRAP1, 
positions F168 and H170 of hMC2R may be important for trafficking and activation. 
Furthermore, Cell Surface ELISA results have shown that there may be more residues 
located in the TM4 and TM5 of hMC2R that are interacting with MRAP1 for successful 
trafficking of the receptor. Due to the drop in trafficking, the single alanine mutants at 
positions I163 and M165 in the TM4 region of the hMC2R are thought to interact with the 
transmembrane domain of MRAP1. Also, single alanine mutants at positions F178, L181, 
and F182 in the TM5 domain of the receptor showed a drop in trafficking. Therefore, these 
positions are thought to interact with the TM domain of MRAP1 as well. These 
interactions between the amino acid residues of the TM4/EC2/TM5 regions of hMC2R 




In the model presented in Figure 35, the activation motif of mMRAP1 (LDYL) 
may directly interact with H170. It is conceivable that the positively charge R-group of 
H170 may ionically interact with the negatively charged R-group of the D residue in the 
activation motif of mMRAP1. In this scenario, F168 at the bottom of EC2, M165 and I163 in 
TM4 either through h-bonding or hydrophobic interactions interact with corresponding 
residues on the TM of mMRAP1 along with F178, L181, and F182 on TM5 to facilitate the 
trafficking of hMC2R to the plasma membrane. Partial support for this scenario comes 
from the cAMP-reporter activation experiments done on TM5 (Dores et al., 2016) which 
indicated that alanine substitution at F178 and L181 significantly impairs activation of 
hMC2R following stimulation with hACTH(1-24). The absence of an apparent effect by 
alanine mutants in the TM4 domain (Dores et al., 2016) as compared to the results 
presented in Figures 32 and 33, would indicate that re-evaluation of the cAMP reporter 
analysis for the TM4 domain of hMC2R is required.  
        Finally, the importance of the proposed interaction between hMC2R and mMRAP1 
as summarized in Figure 35 cannot be overstated. Because of this interaction, hMC2R is 
delivered to the plasma membrane. Without this interaction hMC2R would be stranded in 
the endoplasmic reticulum. Without this interaction, hMC2R once at the plasma 
membrane would not be in the proper conformation to facilitate the proposed two-step 
activation mechanism that is proposed to begin with the binding of the KKRR motif of 
hACTH(1-24) to the EC2 domain of hMC2R and leads to the proposed opening of the 
HFRW binding site on hMC2R and the docking of the HFRW motif of hACTH(1-24); an 




the cytoplasmic side of the plasma membrane and in turn activated adenylyl cyclase to 




CHAPTER 7: Insights on the MC2R/MRAP1 Interaction 
        This thesis has used a chimeric receptor paradigm and an alanine-substitution 
paradigm to tease apart the interaction between hMC2R and mMRAP1. While it was 
known that the N-terminal region of mMRAP1 is required for activating the receptor. The 
results of this thesis point to the possibility that the N-terminal of MRAP1 and the EC2 
domain of the receptor are forming the primary binding site for ACTH. However, the 
actual structure of this proposed binding site cannot be deduced from the approaches used 
in this thesis. Molecular modeling of the MC2R/MRAP1herteodimer is a logical next 
step in understanding the activation of MC2R in bony vertebrates. Since previous and 
current studies on bony vertebrate MC2R orthlogs all point to a common mechanism for 
activating the receptor, perhaps by taking a comparative view of the N-terminal of 
MRAP1 and the EC2 domain of MC2R a perception of this binding domain may emerge.  
 In 2009, studies on the N-terminal of mouse MRAP1 identified an important 
motif for activation (L18D19Y20I21) (Sebag and Hinkle, 2009). In Figure 36, the activation 
motif is identified in red. In this study, a cell surface expression assay and an cAMP 
activation assay showed significant results that lead to this conclusion. Using cell surface 
ELISA analysis this study showed that co-expression of the hMC2R and mouse MRAP1 




the TM of mouse MRAP1 with the TM of RAMP3 (the accessory protein for the 
calcitonin receptor) complete blocked trafficking. Therefore, the TM of MRAP1 is 
responsible for trafficking. What role does the N-terminal domain of mouse MRAP1 play 
in activation of human MC2R? 
 In a cAMP activation assay, co-expression of hMC2R with an alanine subititued 
mutant of mouse MRAP1 in which the L18D19Y20I21 motif was replaced with alanines 
completely blocked activation. To clarify the relative importance of each amino acid 
postion in the L18D19Y20I21 motif, single alanine subsituted mutants were made, and in 
this experiment subititutiion of an alanine at Y20 resulted in a 50% drop in activation. 
However, alanine subitution at L18, D19, or I21 had no negative effect on activation. While 
Y20 is clearly critical for activation, L18, D19, and I21 may contribute collectively to the 
secondary structure of the activation motif, and subtitution at all four positions may have 
disrputed this critical secondary structure. Hence the A18A19A20A21  mutant resulted in no 
activation because of the loss of this critical seondary structure. To compliment the 
activation analysis, a binding assay was done and alanine subititution at the L18D19Y20I21 
motif completley block binding of hACTH(1-24). Prior to this thesis, the binding 
experiment with the A18A19A20A21 analog of mMRAP1 could be explained by assuming 
that the N-terminal of mMRAP1 makes contact with either the N-terminal of hMC2R, or 
the EC1 domain if hMC2R, or the EC3 domain of hMC2R, to cause a conformational 
change expose the KKRR binding site on hMC2R (i.e., the EC2 domain). An alternative 




binding site for ACTH as a result of the forming MC2R/MRAP1 heterodiner.   The 
results of this thesis are consistent with the second hypothesis. 
 More recent experiments may indicate that other motifs in the N-terminal of 
mMRAP1 play a role in the activation mechanism (Malik et al. 2015). In this study, 
phenylalanines were subsititued at postions Y14, Y16, Y17, and Y20 to make a mutant form 
of mMRAP1. When this mutant form of MRAP1 formed a heterodinmer with hMC2R 
there was a 60% drop in activaiton relative to the positive control (wild-type 
hMC2R/mRAP1). These results suggest that Y14, Y16, and Y17 may be involved in the 
activation mechanism. However, their earlier study (Sebag and Hinkle, 2009) observed 
that alanine substitution at Y20 caused a 50% drop in activation when co-expressed with 
hMC2R, hence the role of Y14, Y16,  and Y17 in the activation process is still unclear. 
Future experiments to resolve the role played by each of the tyrosine residues should be 
done using a single alanine substitution paradigm. Finally, as shown in Figure 36 the 
avian MRAP1 ortholog has nearly all of the critical amino acids found in the activation 
motif of mouse MRAP1 (i.e., Y14, Y16,  Y17, D19, Y20, I21). Hence, amniote MRAP1 
orthologs may activate amniote MC2R orthologs through a common mechanism.  
            [----------------N-terminal--------] 
     mMRAP1 MANGTDASVPLTSYEYYLDYIDLIPVDEKKLKANKH 36  
     cMRAP1 MANRTNSSEYFWSYEYYWDYIDPIPVDGRKLKVNKY 
Figure 36: Alignment of the N-terminal of MRAP1 orthologs Figure 36 illustrates the 
N-terminal sequence of the mouse and chicken MRAP1. The areas of primary sequence 
identity outside the activation motif are shown in grey. The aspartic acid (D), the tyrosine 
(Y), and the isoleucine (I) are important residues within the activation motif of MRAP1. 
These three residues are found in cMRAP1 and mMRAP1. These residues are shown in 




Alanine subitituion studies have also been done for the MRAP1 orthologs of two 
bony fishes: rainbow trout(Oncorhynchus mykiss) and zebrafish (Danio rerio) (Dores et. 
al, 2016). As shown in Figure 37, rainbow trout MRAP1 and zebrafish MRAP1 have 
activation motifs very similar to mouse MRAP1. The common amino acids are aspartic 
acid (D) and tyrosine (Y).  Alanine subitiution experiments revealed that both the aspartic 
acid (D) and tyrosine (Y) are requried for activation. Note that these same amino acid 
postions are found in the MRAP1 ortholog of the fugu fish (Takifugu rubriipas) and gar 
(Lepisosteus occulatus). Perhaps for the bony fishes, the aspartic acid (D) and tyronsine 
(Y) positions work together to facilitate activation. The zebrafish and rainbow trout study 
revealed the importance of the D residue in the activation motif. As the results of this 
thesis indicate, the N-terminal of MRAP1 and EC2 together appear to form the binding 
site for the KKRR motif in ACTH. In this regard, the D residue in the activation motif 
may ionically interact with an R-group of one of the basic amino acids in the KKRR 
motif of ACTH. Given this conclusion, perhaps the role of the D19 residue in the 


















        [----------------N-terminal--------] 
 mMRAP1 MANGTDASVPLTSYEYYLDYIDLIPVDEKKLKANKH 36  
rtMRAP1 M------DSWRYEWE-YYDYLDPIPVDERKLKYNKY                   
zfMRAP1 MKNSS---EYVWGYEYYYDYVDPVLVNASTLKYSRY               
fMRAP1  MENST--GTYEW--EYYYDYIEPVIVDESKLKYNKY                
gMRAP1  MANTS---FYVW—-EYYYDYLDPVIVDEKQLKFNKY 
Figure 37: Alignment of the N-terminal of Mouse, Zebrafish, and Rainbow trout 
MRAP1 orthologs Figure 37 illustrates the N-terminal sequence of mouse, rainbow 
trout, zebrafish, fugu fish, and gar MRAP1 orthologs. The areas of primary sequence 
identity are shown in grey. The aspartic acid (D) and the tyrosine (Y) are important 
residues within the activation motif of MRAP1. These residues are shown to be 
universally conserved between all MRAP1 orthologs. These residues are shown in red. 
Abbreviations: m(mouse: Mus musculuss), rt(rainbow trout: Oncorhynchus mykiss), 
zf(zebrafish: Danio rerio), f(fugu fish: Takifugu rubriipas), and g(gar: Lepisosteus 
occulatus). 
 
While alignment of the N-terminal of MRAP1 orthologs and the identification of 
the activation motif as well as additional amino acid postions that may be involved with 
activaiton of MC2R orthologs was fairly straightforward, identifiying amino acid motifs 
in the EC2 domain is more challenging. When focusing on the amniote species there 
appears to be a relatively high degree of primary sequence idenitty in the EC2 domain as 
shown in Figure 38.  
      [---------TM4---------]   EC2   [--------TM5--------] 
   h  RRTVVVLTVIWTFCTGTGITMVIFSHHVPTVITFTSLFPLMLVFILCLYVHMF 196 
   c  QRALVILAIIWTFCAGSSIAIALFSHEVATVIPFTILFPLMMIFILCLYIHMF 
Figure 38: Alignment of the TM4/EC2/TM5 domain of MC2R orthologs Figure 38 
illustrates the TM4/EC2/TM5 domain of the human and chicken MC2R orthologs. The 
areas of primary sequence identity within these domains are shown in grey. The positions 
shown in black are residues that are conserved within the EC2 domain of hMC2R and 
cMC2R orthologs. The positions shown in blue (F168, H170, and F178) are important 
residues within the EC2 and TM5 domain of hMC2R. Previous studies have shown that 
these residues either effect trafficking or activation of the hMC2R. These residues are 
conserved within the EC2 and TM5 domain the cMC2R ortholog as well. Abbreviations: 
h(human:Homo sapiens), c(chicken: Gallus gallus). 
An alignment of the human EC2 and the EC2 domain of the chicken (Gallus 




previous work on the EC2 domain of hMC2R had demonstrated the importance of F168, 
H170, and F178 (Chen et al., 2007, Chung et al., 2008, Dores et al., 2015), it would be 
ressonable to conclude that these corresponding postions in the EC2 domain of the 
chicken should be required for activation of the chicken MC2 receptor. Alanine 
substitution experiments of the three conserved amino acids can confirm or refute this 
hypothesis.  
That said, attempting to draw conclusions with regard to bony fish MC2R 
orthologs is more challenging. Alignment of the ray-finned fish TM4/EC2/TM5 domains 
with the aminote TM4/EC2/TM5 domains indicates minimal primary sequence identity 
for the EC2 domain (Figure 39). Within the EC2 domain of the ray-finned fishes only the 
phenylalanine (F) is universally conserved (Figure 39). Studies by Liang et al. (2018) 
indicated that the phenylalanine in the EC2 domain of rainbow trout does play a role in 
the activaiton mechanism. Alanine substitution at this site resulted in a statisically 
significant drop in activaiton. However, the position that is far more imporatnt for 
activation of rainbow trout MC2R is V166 in the TM4 domain (Liang et al., 2018). It 
appears that there may be a shift in the proposed docking site for the KKRR motif of 
ACTH(1-24) in the ray-finned fishes. However, the Liang et al. 2018 study did not 
resolve whether alanine subtitution at V166 interfered with trafficking. Additional analysis 
of the ray-finned fish sequences also shows that F182 is conserved in the TM5 domain, 
and alanine subsitution at this postion did have a significant negative effect on activation 
of the alanine subsitiuted rainbow trout MC2 receptor (Liang et al., 2018). In addition, 




bigger negative impact on activaiton as compared to alanine subutuition at F178 (Liang et 
al. 2018). This amino acid positon is also conserved in the other ray-finned fish MC2R 
orthologs. Since F182 is located in TM5, this position is most likely playing a role in 
trafficking. This hypothesis can also be tested by cell surface ELISA analysis for alanine 
subsititution at postion F182 for other ray-finne fish orthologs presented in Figure 39. 
However, these experiments on the role that amino acids postions in TM4 and TM5 may 
play in trafficking does not resolve the role of the EC2 domain of the three ray finned fish 
MC2R ortholog in the activation mechanism. 
      [---------TM4---------]   EC2   [--------TM5--------] 
   h  RRTVVVLTVIWTFCTGTGITMVIFSHHVPTVITFTSLFPLMLVFILCLYVHMF  
   c  QRALVILAIIWTFCAGSSIAIALFSHEVATVIPFTILFPLMMIFILCLYIHMF 
   f  QRTGAILGLIWTTCGVSAMLMVRFFDSNLIMSCFVVFFIISLAIIYILYVYMF 
   r  RRAAAALAGIWALCGVAGAVMVAFCDATVIKIFFIVLFLISLLLLLFLYVHMF 
   g  KRVAVILGSIWTFCAGSGVVMIIFFRATVIMTCFIALFLVSLVLILILYVHIF  
Figure 39: Alignment of the TM4/EC2/TM5 domain of MC2R orthologs Figure 39 
illustrates the TM4/EC2/TM5 domain of the human, chicken, fugu fish, rainbow trout, 
and gar MC2R orthologs. The areas of primary sequence identity within these domains 
are shown in grey. The positions shown in black are residues that are conserved within 
the EC2 domain of hMC2R and cMC2R orthologs. Also, the phenylalanines in the EC2 
and TM5 (shown in blue) are universally conserved in the MC2R orthologs. Positions in 
green are conserved in the ray-finned MC2R orthologs. Abbreviations: h(human:Homo 
sapiens), c(chicken: Gallus gallus),f(fugu fish:Takifugu rubriipas), rt(rainbow trout: 
Oncorhynchus mykiss), and g(gar:Lepisosteus occulatus).   
        At present, based on primary sequence identity for the EC2 domain it is difficult to 
explain how this domain serves as the binding site for the KKRR motif of ACTH(1-24). 
It is assumed that the N-terminal domain of the respective MRAP1 is positioned with the 
EC2 domain of the three ray-finned fish sequences presented in Figure 39. The aspartic 
acid (D) in the activation motif of the ray finned fish MRAP1 orthologs (Figure 37) could 
certainly form an ionic interaction with the basic amino acids in the KKRR motif 




the secondary structure of the amino acids in the EC2 domain rather than the primary 
sequence of amino acids in the EC2 domain. In other words, perhaps the EC2 domains of 
the ray-finned fish MC2 receptors while having different amino acid sequences actually 
have similar secondary structures to create the binding pocket. This issue can only be 
resolved through molecular modeling of the heterodimer made up of the MC2 receptor 
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MATERIALS AND METHODS 
Tissue Culture Procedure 
 Experiments were done utilizing Chinese Hamster Ovary (CHO) cells (ATCC, 
Manassas, VA). The cells were grown in Kaighn’s Modification of Ham’s F12K media 
supplied by ATCC. Media was supplemented with 10% fetal bovine serum, 10 unit/ml 
penicillin, 100 µg/ml streptomycin, and 100 µg/ml normacin (Complete CHO media) The 
cells were grown in a 25 cm3 tissue culture flask with vent cap by CELLTREATTM 
(Pepperell, MA), and maintained in an incubator with 95% air, 5% CO2 at 37ºC, and 
exposed to humidity. When the CHO cells reached 70-80% confluence, cells were split 
into new culture flasks using 0.05% trypsin/0.53 mM EDTA produced by CORNING  
cellgroTM (Corning, NY).  
DNA Constructs 
 The human MC2R (hMC2R; Accession #: AA067714.1) cDNA construct was 
synthesized by GenScript (Piscataway, NJ). For activation assays, this receptor was 
tagged at the N-terminus with a FLAG epitope, and inserted into a pcDNA33.1+ vector. 
In addition, the mammalian, Mus musculus (mouse), MRAP1 (mMRAP1; Accession #: 
NM_029844) was synthesized by GenScript, and inserted into a pcDNA3.1+ vector as 
well. The mMRAP1 cDNA was not tagged. This cDNA was used for both activation 
assays and cell surface ELISA assays. The cAMP reporter, CRE-Luc (Chepurny and 




chimeric mutants were made utilizing the human MC2R and Xenopus tropicalis MC1R 
(xtMC1R; Accession#: XP 012817790) where the N-terminal, EC1, EC2, and EC3 of the 
human MC2R were swapped out with the corresponding domains of xtMC1R. These 
chimeric mutants were tagged with a V-5 epitope tag at the N-terminus, and inserted into 
a pcDNA3.1+ vector. Furthermore, cassette and single alanine-substituted mutants of the 
wild type human MC2R were made at the EC1,  and EC3 domains. Each of these alanine 
mutants were tagged with the V-5 epitope. For the cell surface ELISA assays, a set of 
TM4, EC2, and TM5 single alanine mutants were along with a wild-type hMC2R cDNA. 
Each of these cDNAs had a V-5 epitope tag, and were inserted individually into a 
pcDNA3.1+ vector (GenScript).   
ACTH Peptide 
 The melanocortin peptide used in these experiments was human ACTH(1-24), 
and this synthetic hormone was purchased from Sigma-Aldrich Inc. located in Saint 
Louis, MO. The amino acid sequence for human ACTH(1-24) is shown in Figure 7.    
 cAMP Reporter Assay (Luciferase Assay) 
 In the cAMP Reporter Assay, 3.0x106 cells/reaction were used (24 wells of a 
white 96 wells plate = per one reaction). It should be noted that 4 reactions could be 
performed on a white 96 well plate. Cells were co-transfected with the following cDNA 
constructs: hMC2R or chimeric xtMC1R/hMC2R or alanine-substituted hMC2R (10 
nm/rxn), mMRAP1 (30 nm/rxn), and CRE-Luciferase (83 nm/rxn) (Chepurny & Holz, 




(Lonza Group, LTD, MD), 100 µl Solution T/reaction, and program U-23. After a 10 
minute period of recovery in 500 µl of CHO media, the transfected cells were diluted in 
7.5 ml of CHO media. It should be noted that the 600µl of reaction mixture should be 
mixed well in the dilution media, so that the mixture is homogenous and plated 1x105 
cells per well (300µL per well). After about 24 hours after the transfection, cells were fed 
with 300 µl of fresh CHO media.  
On the third day of the cAMP reporter luciferase assay, the transfected cells were 
stimulated with hACTH(1-24) in serum-free CHO Media (does not contain FBS). Serial 
dilutions were carried out with hACTH(1-24) concentrations ranging from 10-7 to 10-13 
M. In addition, each dose was tested in triplicate. Then, the stimulated plate was 
incubated at 37ºC incubator for 4 hours. After the 4 hour stimulation period, the plate was 
allowed to cool to room temperature, and the stimulation solution was removed. Next, a 
1:1 ratio of serum free CHO media and Luciferase substrate reagent Bright GLO 
(Promega, WI) was gently mixed in a 15 mL conical tube. The Luciferase substrate 
solution was applied to each well (100 µL/well), and allowed to incubate at room 
temperature for 5 minutes. Finally, luminescence of each well was measured using the 
Bio-Tek Syngergy HTX plate reader (Winooski, VT).  
Additionally, basal levels of cAMP production needed to be determined to 
produce an accurate activation curve. Therefore, a negative control was included in each 
assay where the transfected CHO cells were not stimulated with wild type ACTH(1-24) 
peptide used in the experiment. The negative control was subtracted from each data point, 




Menton equation to produce an EC50 value for each activation curve. These activation 
curves were analyzed by using Kaleidograph software (www.syngery.com). 
Cell Surface ELISA 
First, a 24-well plate is treated with 500µl of fibronectin in each well to provide 
matrix for the CHO cells to adhere to bottom of the plate. Each reaction contains 6 wells. 
Hence, 4 reactions can be completed per 24-well plate. The fibronectin came from bovine 
plasma, and was reconstituted in 50 ml H2O to provide a final concentration of 1mg/ml. It 
was ordered from Sigma-Aldrich Inc. located in St. Louis, MO. The untransfected CHO 
cells were split using the method stated in section 2a. Each well of the 24 well plate 
needed to contain 0.75 x 105 cells. The cells were left to grow over night in 500µl of 
CHO Complete Media (media recipe found in section 2a.   
The second day of this protocol included the transfection of the cells. The Complete 
CHO media is replaced with new Complete CHO Media (500 µl/each well). Next, 1.6 µl 
of each plasmid (hMC2R-V5, mMRAP1- No Tag, or hMC2R alanine-substituted 
mutants-V5) is mixed with 325 µl of JetPrime buffer in a 1.7ml microcentrifuge tube. 
The equation for how much plasmid used in each reaction was 0.25µg/well/1.0µg/ul x 6.5 
wells. The plasmid/JetPrime Buffer was vortexed and spun down. Next, the JetPrime 
reagent is added to the plasmid/JetPrime Buffer mixture (2:1 ratio; 3.2 µl if only one 
plasmid/rxn or 6.5µl if two plasmids/rxn mixed with JetPrime Buffer) and incubated at 
room temperature for 10 minutes. Then, 50 µl of plasmid/JetPrime mixture was added to 




reagent (Polyplus-transfection S.A, Illkirch, France) is a lipid-based transfection reagent 
ordered from VWR (Randor, PA). 
The third day is where the transfected cells undergo immunostaining using a primary 
antibody and secondary antibody conjugated to HRP. The transfected CHO cells were 
pre-treated with the DMEM + BSA media for 30 minutes in a 37ºC incubator. This media 
is made up of 500 ml of D-MEM media, 5ml of penicillin/streptomycin (final 
concentration 1mM), 10ml of HEPES (stock solution of 1M and final concentration at 
20Mm), and 500mg of BSA (final concentration of 1 mg/ml). Next, the primary antibody 
(mouse anti-V5) is diluted in the primary antibody in transfection media (1:1000) in a 
15ml centrifuge tube. While making up the primary antibody, the plate is incubated on 
ice for 10 minutes at room temperature. After primary antibody is made up, replace 
media with the DMEM + BSA media + primary antibody mixture and incubate on ice for 
1 hour at room temperature. Note that only half of the plate will be treated with the 
primary antibody.  
After 1 hour, the cells need to be washed four times with 500µl/well of ice cold 1 x 
PBS. Next, the transfected wells need to be fixed with 300µl of 4% PFA on ice for 5 
minutes. After the cells are fixed, the wells need to be washed 2 times with 500µl/well of 
ice cold 1 x PBS. The secondary antibody (goat anti-rabbit-HRP or goat anti-mouse-
HRP) is prepared in the DMEM + BSA media and diluted to a concentration of 1:1000. 
All reactions are treated with the secondary antibody at 300µl/well, and incubated at 
room temperature for 1 hour. While incubating with the secondary antibody, an aliquot of 




1-step solution is a water-soluble peroxidase substrate that turns green when exposed to 
secondary antibody that is conjugated to HRP. The ABTS 1-step solution was ordered 
from Thermo-Scientific (Waltham, MA). After the 1 hour incubation period, the 
secondary antibody needs to be removed, and washed 4 times with 1 x PBS. Next, the 
wells are treated with 300 µl of ABTS 1-step, and incubate at room temperature for 25 
minutes. If there was presence of receptor on the surface of the cells, the ABTS 1-step 
substrate yields a green end product. Each reaction well is transferred into 96-well plate 
(100ul/well), and the absorbance is read at 405nm Bio-Tek Synergy HTX plate reader 
(Winooski, VT).  For all cell surface ELISA assays the following controls were used: 
non-transfected CHO cells  incubated with primary and secondary antibodies, CHO cells 
transfected with only hMC2R cDNA and incubated with primary and secondary 
antibodies, and CHO cells transfected with hMC2R + mMRAP1 cDNAs and incubated 
with primary and secondary antibodies (positive control).   
Statistical Analysis 
 Data points were calculated as a mean with standard error values that were 
obtained from experiments performed in a triplicate. To determine statistical significance 
between experimental treatments and their corresponding controls, an unpaired two-tailed 
Student’s t-test for equal variance was calculated; significance was set at P ≤ 0.05 for 
Figures 10B, 12, 13, 19A, 19B, 25. In addition, the data sets for Figures 10A, 15, 16, 17, 
20, 21, 23, 27, 32, 33, 34.were analyzed using a one-way ANOVA, and then by Tukey’s 




calculated using the GraphPad Prism 2 software (GraphPad Software Inc., La Jolla, CA, 
USA). Significance was set at p ≤ 0.05. 
